Full Report

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Industry in One Page

Sagility operates in U.S. healthcare operations outsourcing — running the administrative, clinical, and member-facing back office for U.S. health insurers, hospitals and physicians, and pharmacy benefit managers. The work is non-discretionary: claims must be adjudicated, appeals reviewed, members enrolled, providers credentialed, and bills sent every day a U.S. health plan is open. Money flows from a small group of very large payers and hospital systems down through a $48-49 billion outsourced wallet (2024) into a handful of global vendors that deliver from India, the Philippines and the Caribbean while keeping U.S.-based clinical and onshore staff. Margins exist because (a) U.S. wage arbitrage against offshore labor is wide, (b) HIPAA-grade compliance, payer/provider contracts, and 5-7 year implementation cycles make switching expensive, and (c) regulated clinical work (utilization management, payment integrity, Star ratings, risk adjustment) can only be done by trained humans. This is not generic BPO: the unit sold is a domain-trained human — coder, nurse, claims adjudicator — wrapped around a HIPAA-compliant workflow, and the customer's pain is regulatory complexity, not just cost.

Takeaway: a small set of very large U.S. payers sits at the top of a $48-49 billion outsourced wallet; vendors compete on domain depth and offshore unit cost.

How This Industry Makes Money

A healthcare BPM vendor sells one of three units: an FTE-month (a trained agent or clinician dedicated to a client), a per-transaction fee (per claim adjudicated, per call handled, per chart coded), or an increasingly common outcome-based fee tied to denials recovered, dollars saved through payment integrity, or Star-rating gates met. Revenue is recurring under 3-7 year MSAs with rolling SOWs; clients can terminate for convenience, but rarely do — Sagility's disclosed top-5 average tenure is 18 years, and industry retention runs above 95% for established vendors.

The cost stack is roughly 65-72% people (wages, benefits, training, attrition replacement), 8-12% technology and licenses, 8-12% facilities and delivery, residual SG&A. Because most agents sit in India and the Philippines, every point of INR/PHP wage inflation, every basis point of FX move, and every attrition cohort re-trained shows up in margins within two quarters.

Takeaway: the profit pool tilts away from voice/data-entry and toward clinically licensed and analytics-led work; that's where price holds and where AI displacement is slowest.

Capital intensity is modest. Tangible capex runs 2-4% of revenue; the bigger capital story is acquisitions — payment-integrity specialists, GenAI startups, and regional onshore players — which is how every public peer (EXL, Genpact, WNS, Sagility) has filled capability gaps. Bargaining power sits with the top three or four U.S. payers, who can dictate price, demand productivity give-backs, and audit vendors at will; the vendor's only counter is operational stickiness and the cost of switching a 5,000-FTE program.

Demand, Supply, and the Cycle

Demand is driven by the non-discretionary mechanics of U.S. healthcare itself. The U.S. healthcare market reached $5.26 trillion in 2024 (~18% of GDP), and CMS projects $6.62 trillion by 2028 (5.9% CAGR). The operations layer — the back office of payers and providers — was $211 billion in 2024 and is projected to reach $253-263 billion by 2028.

The cycle hits the operations layer differently than the broader system. Three drivers move the needle:

Unlike commercial banking BPO or telco contact centers — which see calls drop in a recession — healthcare ops volume is anchored to membership and claims volume, both stable to growing through downturns. That structure is why the industry trades at a premium to generic BPO and why the 2025-26 hospital cost crunch reads as a tailwind for vendors. The vulnerable end is the routine voice-and-data-entry layer, where GenAI is lowering per-transaction prices.

Competitive Structure

The industry is fragmented at scale with consolidation accelerating. No listed pure-play has more than mid-single-digit share of the $48-49 billion outsourced wallet; Sagility itself estimates its share at ~1.2%. The competitive set sits in concentric circles:

Two structural facts shape competition: (1) buyer-side concentration exceeds seller-side — the top 5 U.S. payers buy a meaningful slice of outsourced healthcare spend, and a single deal win or loss can move a mid-cap vendor's growth rate by 500 basis points; (2) scale matters less than depth — Concentrix is 15x Sagility's revenue but operates at negative GAAP margins because its mix is contact-center, not regulated clinical ops. Sagility runs the cohort's highest operating margin because the mix is right.

Regulation, Technology, and Rules of the Game

The industry exists because U.S. healthcare is the most heavily regulated services market in the developed world. Every change to CMS rules, HIPAA, state TPA licensing, or coding standards either creates work or destroys it.

The biggest framing question is GenAI. The bull case (and the case Capgemini paid $3.3 billion for WNS to validate in October 2025) is that intelligent-operations platforms expand the BPM pie by automating end-to-end processes previously too complex to outsource. The bear case is that voice and routine claims processing — ~25% of healthcare BPM by revenue — sees per-transaction prices fall 30-50% over five years as AI displaces FTEs. Both are partially true; the regulated clinical mix is where the regulatory moat survives.

The Metrics Professionals Watch

Generic accounting ratios don't separate winners here. Seven do.

Two pseudo-KPIs to ignore: gross-margin disclosure (presented inconsistently — cost of revenue includes delivery wages for some, excludes them for others), and headcount growth on its own (without a revenue-per-FTE pairing, it's just a count). Track the mix, not the headline.

Where Sagility Ltd Fits

Sagility is the only listed pure-play U.S.-healthcare BPM vendor globally after Capgemini's acquisition of WNS in October 2025. It is small in absolute revenue ($652M FY25 → $767M FY26) but holds the highest operating margin in its peer group because the mix is right and the brand is built for one buyer pool.

One sentence to carry forward: Sagility is a focus-and-margin story trading on Indian multiples while serving a US healthcare wallet that grows 5-7% per year and outsources 23-25% of its operations spend. That tension — Indian valuation framework, U.S. customer base, healthcare regulatory moat — is the arena in which every later tab plays.

What to Watch First

These seven signals tell you, faster than headline revenue prints, whether the industry backdrop is improving or deteriorating for Sagility.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bottom Line

Sagility is the world's only listed pure-play U.S. healthcare payer-BPM operator: an INR cost base translating regulated, non-discretionary U.S. payer back-office work into rupee earnings. The engine is wage arbitrage protected by HIPAA-grade compliance, 18-year top-client tenure, and a clinical mix that AI cannot easily strip. The risk the market debates is AI commoditisation; the actual risk worth watching is client concentration at ~60% top-3 wallet share. Valuation belongs on through-cycle FCF and incremental capital efficiency, not the headline P/E that looks expensive against generic Indian BPM and cheap against the Capgemini-WNS transaction multiple.

How This Business Actually Works

Sagility sells one core unit: a domain-trained human — offshore claims processor, U.S. nurse reviewer, coder — wrapped inside a HIPAA-compliant workflow, sold to U.S. payers under multi-year MSAs with rolling SOWs. Revenue is USD (89.7% payers, 10.3% providers FY26); cost is INR. Everything else — the technology pillar, the AI demos, the practice areas — is built around that single transaction.

Takeaway: the unit being sold is a regulated-human-hour denominated in USD and costed in INR; that single arbitrage is the entire return engine.

The economics get interesting on a ROE decomposition. Reported ROE is ~11% — pedestrian for a 24% EBITDA-margin business. The cause is a balance sheet stuffed with intangibles from EQT's 2021 carve-out of HGS healthcare: ~$997M of fixed assets (mostly goodwill and customer intangibles) sit on ~$1,030M of equity. Stripping carve-out goodwill, management-reported ROCE against working capital plus delivery infrastructure runs above 50%. That is what the business earns on incremental capital; headline ROE is the LBO legacy.

The Playing Field

Sagility is small in absolute revenue but the highest-margin focused player in the listed BPM peer set, and is now the only listed pure-play in U.S. healthcare BPM after Capgemini took WNS private in October 2025. The relevant peer cohort is not "Indian IT services"; it is U.S./global BPM vendors with named healthcare segments, plus Firstsource as the local valuation anchor.

Takeaway: Sagility is the only dot in the top-right — 100% healthcare focus and the highest operating margin in the cohort. Concentrix and Conduent prove that scale without the right mix destroys returns.

Three things this peer set proves:

First, scale without mix doesn't earn. Concentrix has 13x Sagility's revenue and runs at negative operating margins because the mix is voice-CX. Conduent's healthcare-payer segment is 35% of revenue and the consolidated business still loses money. The moat is not delivery-footprint size — it is the share of revenue tied to regulated clinical work.

Second, the right comp is WNS pre-acquisition, not "Indian IT". WNS had a similar fiscal year (March), a similar delivery model, and a 23% healthcare mix; Capgemini paid ~$3.3bn at ~2.5x revenue. That sets a transaction floor for a pure-play. Sagility trades around 2.6x EV/revenue — already at parity — so the WNS comp is no longer cheap insurance.

Third, Firstsource is the local valuation anchor. The only India-listed BPM peer, trading on ~25x P/E with 16% margins, 9% USD revenue growth, and 17.7% ROE. Sagility's ~20x P/E with higher margin and faster growth but lower headline ROE is the trade the market is making — a focus-and-margin premium offset by an LBO-bloated balance sheet.

Is This Business Cyclical?

No: this is one of the least cyclical businesses in BPM, because the work being outsourced — claims adjudication, member enrolment, provider credentialing, payment integrity, utilisation management — is non-discretionary for U.S. payers. Revenue tracks membership (stable to growing) and claims volume (anchored to enrollment), not GDP. The FY22–FY26 record confirms it: revenue compounded through post-COVID wage inflation, the FY23 Indian BPM wage cycle, the FY24 Medicaid redetermination spike, and the FY25 hospital-cost crunch.

What is cyclical is seasonality, not the cycle. Q3 and Q4 (October–March) capture the U.S. Annual Election Period and Open Enrolment surge — management disclosed seasonal revenues at 6% of FY26 vs 3% of FY25, a known and bookable working-capital swing. The medium-term cyclicality that matters is on the cost side: INR/USD FX (rupee weakness = direct margin tailwind), Indian wage inflation, SEZ tax-holiday rolloff. None are demand cycles; all are input-cost cycles.

The Metrics That Actually Matter

Generic ratios (P/E, ROE) miss the picture because of the goodwill-loaded balance sheet and FX-and-wage cost-stack mechanics. Five metrics actually move the stock.

Takeaway: the concentration concern is real but trending in the right direction — top-3 share has fallen ~600 bps over 3 years while the count of $20mn-plus clients has more than doubled.

Two often-quoted metrics to discount: headline ROE (distorted by carve-out goodwill) and INR-reported revenue growth (flattered by FX; the honest read is constant-currency).

What Is This Business Worth?

Value this as one economic engine, not sum-of-the-parts. Provider RCM is only ~10% of revenue and shares the same delivery infrastructure, cost base, and contract structure as the payer book — separating it would be precision theatre. No listed subsidiaries, no holdco structure, no orphan assets. The right lens is normalized FCF and reinvestment runway, sense-checked against the closest transaction comp (Capgemini-WNS, ~13x EV/EBITDA at deal close).

Underwriting frame: at ~20x trailing P/E and 8.4x EV/EBITDA, the stock is paying for ~13% earnings growth and 24–25% steady-state margin. The Capgemini-WNS deal anchors the strategic ceiling at ~2.5x EV/revenue (Sagility already there); the Firstsource listed-peer P/E sits in a similar zone. The asymmetry: the WNS deal removed the closest comp — anyone wanting clean exposure to listed U.S. healthcare BPM has exactly one ticker. That scarcity is not in the public-comp multiple yet.

What I'd Tell a Young Analyst

Five rules for following this stock without losing your way.

Watch concentration, not the AI debate. The dominant tail risk is a top-three payer renegotiating or insourcing, not GenAI deflating the book. Concentration is below 60% and trending down — every quarterly deck shows the direction. The AI debate is real but second-order; the regulated clinical mix gives two years of cover.

Track constant-currency organic growth, not the INR-reported line. Reported growth was 29.1% in FY26; organic CC was 15%. The gap is FX + BroadPath, not operating performance. Anyone selling the stock on "30% growth" is mismeasuring.

The right peer is not Indian IT. Anchor on Capgemini-WNS at ~13x EV/EBITDA and EXL Health at the segment level — not TCS or Infosys multiples.

Don't be impressed by reported ROE. Eleven percent ROE is the LBO-goodwill artifact; underlying operating returns are multiples of that. Management's "adjusted ROCE" (above 50%) is what the business compounds incremental capital at, and it explains why a 24% EBITDA business gets a 20x multiple rather than a 10x one.

The thesis breaks if margins slip below 22% AND organic CC growth slips below 10%. Each alone is recoverable. Both at once means the FX-tailwind story has unwound while client-side pricing has softened — the only configuration justifying a serious de-rating. Until that combination appears, the default underwrite is through-cycle FCF compounding around the WNS transaction multiple, with option value on EQT eventually selling the residual ~51% stake.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Long-Term Thesis in One Page

The 5-to-10-year thesis: Sagility compounds revenue in the low-to-mid-teens (CC) at a 22–26% adjusted EBITDA margin by selling regulated, non-discretionary U.S. healthcare back-office work that grows with payer membership and tightens with every CMS rule change — and owner value is built less by multiple expansion than by FCF compounding into a near-cash balance sheet that funds disciplined tuck-in M&A. This is not a "great compounder" story in the Indian IT-services sense; it is a focused, mix-led arbitrage where the 24.5% operating margin is roughly two-thirds structural (regulated clinical mix CMS rules require be done by licensed humans) and one-third cyclical (cumulative INR weakness and SEZ tax-holiday tailwind that will unwind).

The case requires the regulated-clinical 75% to preserve pricing while the routine 25% absorbs AI deflation without dragging group margin below 22%. The case breaks if either (a) a single top-3 payer renegotiates or insources at a 5%+ price-down before diversification reaches sub-55% top-3 share, or (b) the EQT pledged-stake overhang resolves through a discounted block rather than a strategic acquirer at the Capgemini–WNS take-out multiple. The single most consequential evidence ahead is whether outcome-based (Synchrony) revenue scales into a disclosed P&L line — that one disclosure resolves both the margin-durability and AI-deflation questions for the entire holding period.

The 5-to-10-Year Underwriting Map

Six drivers carry the multi-year case. Each is rated on evidence today, not on management's stated targets.

Driver 2 — mix shift to regulated-clinical and outcome-based — is the one that matters most. The other five are anchored in industry structure or balance sheet, both easier to predict. Mix shift is the single variable that turns "narrow moat compounder" into "wide moat compounder" — or leaves it as a 20% margin business once FX tailwinds unwind. Every five-year valuation lens hinges on whether Synchrony scales from prepared-remarks-bullet to disclosed-revenue-line.

Compounding Path

The compounding picture sits in three layers: a regulated demand layer that compounds 7-9%, a mix layer that adds 200-400 bps of margin over five years if Synchrony works, and a balance-sheet layer that turns 90% cash conversion into reinvestable dry powder. Each layer is testable.

The FY22-FY26 record establishes the compounding mechanics: revenue at ~19% CAGR in INR (12-15% CC stripping FX); operating margin held in a 400 bps band through three shocks (post-COVID wage inflation, Medicaid redetermination, hospital cost crunch); ROCE from single-digits to mid-teens as carve-out goodwill amortised and debt halved twice. The next phase tests the same engine against a different headwind — AI per-transaction deflation on routine work — and a different tailwind — outcome-based contracting on the clinical book.

Two pieces of math to keep in front. First, every $100M of FCF compounded at the underlying business return adds ~5% to book value per share with no dilution — that mechanical compounding is the real long-term thesis, not multiple expansion. Second, the difference between base and bull cases is almost entirely the mix question, not the macro — if Synchrony scales, 24% margin becomes 26%; if not, 24% becomes 21%. Macro outsourcing tailwinds and INR/wage dynamics are the noise layer, not the signal.

The balance-sheet path is the most predictable lever. Full debt repayment by end-FY27 (already guided, slipped once from end-FY26) frees ~$110-130M/yr of FCF. The question is not whether the capacity exists — it does — but whether management deploys it into accretive M&A, raises payout to 25-30%, or hoards cash for a megadeal that destroys returns. The first dividend (~$0.002/share FY26) is a signal of intent; the next 24 months will show whether it ramps.

Durability and Moat Tests

Five tests separate "durable compounder" from "good-while-it-lasted." Three competitive, two financial — both ends have to work.

Management and Capital Allocation Over a Cycle

The case for trusting management over five years rests on three observable facts and one structural gap. CEO Ramesh Gopalan (IIT-D / IIM-A) ran this exact business inside Hinduja Global Solutions before the 2022 carve-out — public-company tenure is short (since June 2024), but operating tenure on the underlying asset is over fifteen years. Across seven earnings calls since IPO, he has raised guidance three quarters in a row, delivered margin above the upper bound of every band set, repaid two-thirds of carve-out debt while funding the BroadPath acquisition, and initiated a maiden dividend — all without primary capital from the public market. Capital allocation has followed a recognisable PE-trained playbook: deleverage first, then capability M&A (Devlin, BirchAI), then distribution M&A (BroadPath at 0.83x revenue), then a small first dividend. Each step is rational, sequenced, and shareholder-friendly given the controlling shareholder's stated intent to exit.

The structural gap is alignment. EQT has cut its stake from 82.4% to 50.95% in 12 months across two OFS rounds; 100% of the residual is pledged; no executive has bought a single share in the open market post-IPO; the ESOS 2026 pool of 3.30% of equity has yet to be priced or vested. The CFO seat has turned over twice in six months without explanation. Through 2031, the controlling shareholder will almost certainly be different from today's — either a domestic strategic, a U.S. payer (improbable but possible), a Capgemini-style global strategic, or simply a dispersed institutional float. The capital-allocation track record under EQT is solid; the question is whether it survives a transition during which the operator's incentive plan (ESOS strike, vesting hurdles) is set during the sell-down window, by the same controlling shareholder that is selling.

Read it this way: the capital-allocation playbook is rational and on-strategy under EQT — deleverage, tuck-in capabilities cheaply, diversify distribution at sub-1x revenue, return the first crumb of capital once leverage is gone. The five-to-ten-year question is not whether this management can execute the next BroadPath; it is whether the next anchor will demand the same discipline. If a U.S. strategic acquires the residual stake, the playbook may accelerate; if EQT distributes into a dispersed float without an anchor, governance falls to the board alone — independent-majority but tech/cyber thin for a HIPAA-regulated AI services business.

Failure Modes

Five real thesis-breakers — each maps to a specific observable, not generic execution risk.

What To Watch Over Years, Not Just Quarters

Five observable milestones on multi-year clocks that update the thesis materially. None moves on a single quarterly print.

The long-term thesis updates most if Synchrony / outcome-based revenue scales into a disclosed P&L line by the FY28 Annual Report and exceeds 20% of new ACV by FY29. That single sequence validates the mix-shift moat, neutralises the AI-deflation bear case at the operating-margin line, and supports a multiple closer to the Capgemini-WNS strategic ceiling. Everything else — concentration trend, payout ratio, anchor identity — adjusts the slope of compounding; the Synchrony disclosure changes the shape of the curve.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Competitive Bottom Line

Sagility owns a real but narrow moat: the only listed pure-play in U.S. healthcare payer BPM after Capgemini took WNS private in October 2025, with the highest operating margin in the listed peer set despite the smallest revenue base. The moat sits in three reinforcing layers — multi-decade payer contracts (one 25-year relationship; top-5 average tenure 18 years), NelsonHall NEAT 2026 Leader designation in Healthcare Payer Agility & Innovation, and an INR cost base wrapped in HIPAA-grade compliance — durable as long as the work stays regulated, clinical, and non-discretionary. The competitor that matters most over the next 24 months is Capgemini-WNS: the combined entity bundles a BPM book Sagility competes with against an IT-modernisation arm Sagility cannot match. The moat weakens — but does not break — at the routine voice/claims end where GenAI compresses per-transaction prices and private peers (Omega, GeBBS, IKS, AGS) win mid-market deals on price.

The Right Peer Set

The peer universe is anchored on the NelsonHall NEAT 2026 Healthcare Payer Agility & Innovation evaluation — the only published analyst grid that places Sagility in competitive context — narrowed to listed pure-plays and BPM majors with named healthcare verticals, excluding broad IT-services firms where healthcare is under 15% of revenue. Five primary peers plus one supplementary (Conduent) cover the economic shapes that matter: pure-play healthcare arbitrage (Sagility, WNS pre-deal), BPM majors with healthcare slices (EXLS, G, CNXC), the India-listed valuation anchor (FSL), and the declining U.S. legacy BPS (CNDT).

Excluded from the peer set: Cognizant (TriZetto is ~30% of revenue but is dominated by financial-services IT), Wipro / Infosys / TCS / HCLTech / Atos / DXC (healthcare BPM is <5% of revenue; they only compete on transformation-led platform bids), R1 RCM (taken private 2024; no public comp), Omega / GeBBS / AGS / IKS Health (private pure-plays — best economic comps but no listed valuation).

Notes: Sagility market cap and EV converted at ₹1 = $0.01053 (06-Jun-2026); FSL EV unavailable on a single primary source within the data window; WNS values reflect the Capgemini transaction price (US$3.3 bn EV, closed 17-Oct-2025), as live trading data ceased. CNXC P/E n/m due to FY25 loss; CNDT and WNS n/m for the same reason. Sources: peer_valuations.json, screener.in/FSL, FY25/FY26 10-Ks for U.S. peers, FY26 Sagility Q4 deck.

Takeaway: focus and margin move together. Every peer to the left of Sagility runs a lower margin because the mix is wrong; the two peers with the highest healthcare share but a different mix (CNXC at voice CX, CNDT at government Medicaid) actually lose money.

Where The Company Wins

Four advantages stand up to evidence rather than slogan.

1. The only listed pure-play after the WNS exit. NelsonHall NEAT 2026 names eleven vendors in Healthcare Payer Agility & Innovation; after WNS delisted on 17-Oct-2025, Sagility is the only listed name in that grid that is 100% U.S. healthcare. Any global allocator wanting clean, mark-to-market exposure to U.S. healthcare BPM has exactly one ticker. Evidence: NelsonHall NEAT 2026; Capgemini press release 21-Jul-2025; SEC Form 15-12G filed 27-Oct-2025 by WNS.

2. Highest operating margin in the listed cohort. Sagility runs 24.5% FY26 operating margin against a 14-16% band for Genpact, EXLS, Firstsource and pre-deal WNS, and against outright losses at CNXC and CNDT. The gap is not delivery efficiency — every Indian-listed peer runs the same arbitrage — it is the absence of low-margin voice/CX and the presence of clinical, payment-integrity, risk-adjustment and Star-ratings work the rest of the cohort cannot match in volume. Evidence: FY26 Sagility Q4 deck (adj EBITDA 25.3%); FY25 10-K filings for G, EXLS, CNXC, CNDT.

3. Embedded 18-year average tenure with the U.S. top-3 payers. Sagility serves six of the top-ten U.S. health insurers; top-5 average tenure is 18 years; one named relationship crossed 25 years (FY25 AR). Top-3 wallet share fell from 72.4% (FY23) to 59.9% (FY26) while the top-3 grew at a 9.1% CC CAGR — clients growing and concentration falling is the hardest moat signal to fake. Evidence: FY26 Q4 deck KPI table; FY25 AR p.288-349 ("25 Years with a Top U.S. Payer").

4. INR cost base inside a HIPAA-grade workflow. ~65-72% of Sagility's cost stack is people, dominantly INR-paid; revenue is dominantly USD. The same arbitrage exists at FSL — but FSL runs 16% operating margin because only ~32% of its book is healthcare and it carries BFS contact-centre work. The arbitrage is only valuable where the workflow cannot be commoditised; HIPAA + state DOI licensing + URAC/HITRUST certification make the surrounding regulatory wrapper the actual moat. Evidence: FY26 cost stack disclosure; Sagility AR FY25 "Multi-shore delivery" section.

Where Competitors Are Better

Four real gaps, each named by the competitor that exposes it.

1. Scale-led AI platform R&D — Genpact and EXLS. Genpact spent ~$170 mn on technology R&D in FY25 on a $5.1 bn revenue base; EXLS deploys EXL Code, EXL Insurance LLM and an EXL Health Genome platform on $2.1 bn revenue. Sagility's SmarTec, Synchrony and BirchAI assets are real (BirchAI acquired Mar-24) and have NelsonHall/Everest validation, but absolute R&D dollars are smaller. On the largest payer-transformation deals — where vendor selection now requires a proprietary GenAI platform commitment — Sagility is the specialist sub-bidder, not the prime.

2. The Capgemini-WNS combined offer. Capgemini paid ~$3.3 bn for WNS (closed Oct-2025) explicitly to combine intelligent operations with end-to-end IT modernisation. The combined entity can bid a single proposal covering payer core-admin platform modernisation, WNS's healthcare BPM book, and Capgemini's existing payer consulting practice. Sagility cannot match the IT-services arm; on any deal where the customer wants one throat to choke for both platform replacement and operations, Sagility is structurally disadvantaged. Risk concentrates in 2026-27 as go-to-market integration completes.

3. Provider RCM sub-scale — vs Firstsource and private peers. Sagility's provider book is ~10% of revenue (~$77 mn FY26). Firstsource runs a larger provider-RCM stack within its ~$1,019 mn healthcare-tilted book. Private peers (Omega Healthcare, IKS Health, AGS Health, GeBBS) are pure-play provider RCM and the natural choice for hospital systems that want a specialist vendor. The Devlin (Apr-23) and BroadPath (Jan-25) deals grew the RCM book, but the provider mix is small enough that the business is best understood as payer-led with an attached RCM option.

4. Diversified BPM downturn resilience — Genpact and EXLS. When U.S. payer profitability compresses (as in 2024-25 with MLR ratios spiking at Centene, Humana, Elevance), Sagility's revenue stays anchored to claim volume — but pricing renegotiations are concentrated. Genpact and EXLS spread the risk across BFSI, telecoms and analytics verticals; a 5% per-transaction price-down on healthcare claims hits Sagility's margin harder than a diversified BPM's. Cycle resilience at the operating-margin line is structurally lower.

Takeaway: Sagility's two genuine 5s are pure-play focus and operating margin; its two genuine 1s are IT modernisation and government Medicaid. The Capgemini-WNS combination is the only peer that scores 5 across both AI platform R&D and IT modernisation bundle.

Threat Map

Moat Watchpoints

Five signals tell an investor faster than headline revenue whether the moat is widening, holding, or eroding — all measurable in Sagility's quarterly KPI table or in named peer filings.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Current Setup in One Page

The stock closed at $0.42 on 5 June 2026 — round-tripping the entire 2025 rally back to mid-IPO levels. Three watchpoints dominate: (i) whether the FY27 "low double-digit CC, 24–25% adj EBITDA" guide proves as conservative as FY26's did, (ii) when EQT clears the next slug of its 100%-pledged 50.95% residual stake, and (iii) whether the ESOS 2026 postal ballot (launched 31 May 2026) sets a credible strike and performance hurdle for management equity issued during the controlling-shareholder sell-down. Setup: Mixed. Operational delivery is the cleanest credibility track on the Indian mid-cap BPM tape (FY26 guide raised three quarters in a row, FY27 guide already deemed sandbagged by sell-side); the tape, the promoter pledge, two CFO transitions in six months, and the soft FY27 starting guide are all live drags. The first real underwriting update is the Q1 FY27 print, due in the last week of July 2026.

What Changed in the Last 3–6 Months

The narrative arc of the last six months is a single sentence: the market priced the EQT exit, then priced the AI deflation, and is now pricing the conservatism of the FY27 guide as if it were a downgrade — even though management's track record across seven quarters since IPO is twelve "met-or-beat" outcomes against fifteen disclosed promises. What investors used to worry about (concentration, GenAI cannibalisation as a binary threat) has been reframed by management with credible numbers — top-3 fell below 60%, AI deployed across 8 clients in 18 use cases. What they worry about now is unresolved: the Synchrony revenue line is still narrative-only, the BroadPath cross-sell stalled at AEP, the next EQT OFS clearing price is unknown, and the FY27 margin band implicitly walks back the FX tailwind that built the 24.5% print. The Q1 FY27 cadence resolves the conservatism question and reframes the rest.

What the Market Is Watching Now

Ranked Catalyst Timeline

The ranking below is decision-value first, chronology second. A high-impact catalyst with a soft date is ranked above a low-impact catalyst on a hard date.

Impact Matrix

The matrix below filters the timeline down to the catalysts that genuinely update durable thesis variables, not just one-quarter noise.

The honest read: three of these five update the long-term thesis, not just the next quarter. The Q1 FY27 print and the AEP cycle are near-term evidence — important but not by themselves underwriting-changing. The Synchrony disclosure, the OFS pricing, and the ESOS structure are the three that move the curve, not just the slope.

Next 90 Days

The 90-day calendar is adequate but not deep: one earnings print, one postal-ballot outcome, one AGM, one peer-read window. The events with the largest decision value — the next EQT OFS, the first quantified Synchrony number, and the next named BroadPath cross-sell — are all outside the 90-day calendar with soft dates. A PM running this name through summer is implicitly underwriting that the Q1 FY27 print holds the FY27 guide tone, that the ESOS result does not surface a strike-pricing controversy, and that the EQT OFS does not arrive before the print. Any one of those breaking is the trigger to revisit position size.

What Would Change the View

Two observable signals would change the investment debate most over the next six months. First, the Q1 FY27 print is the single bilateral data point — beat-and-raise consistent with the FY26 cadence (CC growth 14%+, margin sustaining at 24.5%+, AI cannibalisation contained at 2%) crystallises the bull's "credibility track + scarcity premium + FCF compounder" case and opens the 12-month re-rating window toward $0.53–$0.59; a sub-12% CC, sub-23.5% margin print is the explicit bear primary-trigger configuration and pulls the multiple toward the 15x Indian-BPM-cohort discount. Second, any disclosure that makes Synchrony tangible — a named outcome-based deal beyond the Convey/Simplify alliance, a percent-of-new-ACV number, or a P&L line item in an investor deck — is the single piece of evidence that resolves both the AI-deflation bear case (at the operating-margin line) and the Long-Term Thesis mix-shift driver simultaneously. The two tail signals worth pricing alongside are the next EQT OFS clearing price (calling the structural floor under the stock) and the ESOS 2026 strike-pricing decision (calling management alignment through the anchor-shareholder transition). Everything else on the 90-day calendar — the AGM, the GST demand resolution, the HIRE Act tracker — is texture, not signal.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — both sides anchor to the same testable thresholds in the next two FY27 prints, and the controlling-shareholder overhang argues against committing capital before those prints land. Bear carries slightly more weight today: three data points (FX-stripped organic growth ~15%, ICRA's top-3 disclosure at 65% versus management's 59.9%, and the EQT sell-down from 82% to 51% with 100% of the residual pledged) converge on the same "headline overstates the economics" reading. Bull's structural case — the only listed pure-play U.S. healthcare BPM after Capgemini delisted WNS at 16.3× EV/EBITDA, with peer-leading 24.5% margins and a near-zero net-debt sheet — is real but is not setting the marginal price. The decisive test is whether FY27 adj EBITDA margin holds above 22% while top-3 concentration prints below 60%; that one print addresses both the margin-durability and concentration-disclosure tensions.

Bull Case

Bull's scenario value is ~$0.79 over 12-18 months if FY27 prints validate the structural read, derived as 25× FY28E EPS of ~$0.032 and cross-checked against ~12.5× FY28E EV/EBITDA — half the gap between today's 8.7× and the Capgemini-WNS 16.3× strategic take-out. The 25× exit multiple sits below the 38× post-IPO peak (when the business carried more debt and less client diversification) and below Inventurus Knowledge Solutions at ~39× trailing. Bull's disconfirming watchpoint: top-3 concentration ticking back above 62% and adj EBITDA margin slipping below 22% in the same quarter — the configuration consistent with the focus-and-margin premium breaking.

Bear Case

Bear's scenario value is ~$0.32 per share over 12 months if the FX-tailwind and concentration reads play out — the IPO listing-price floor, 25% below the current $0.42. Method: strip ~300 bps of FX-driven margin (24.5% → 21.5%), take the 12% organic-CC top-line guide at face value, derive FY28 EPS of ~$0.021, and apply a 15× P/E — the Indian-BPM discount multiple for a sub-mid-teens grower with falling ROE and a PE-exit overhang. Bear's cover watchpoint mirrors bull's disconfirm: top-3 concentration printing below 55% while adj EBITDA margin holds at or above 25% — evidence the diversification is real and supportive of a re-rating toward the WNS strategic multiple. A second-best forced cover would be a credible strategic bid (Genpact, Cognizant) above $0.58 before the FY27 estimate cuts.

The Real Debate

Verdict

Watchlist. Bear carries more weight today because three independent data points — the 15% FX-stripped organic growth rate, the 500 bps gap between ICRA's top-3 disclosure (65%) and management's KPI (59.9%), and an EQT sell-down with 100% of the residual pledged — converge on the reading that headline numbers overstate the underlying economics, while the price action (death cross 20 Mar 2026, distribution on shrinking volatility) is already pricing it. The central tension is whether the 24.5% operating margin is structural mix or FX-juiced; that variable, testable in the next two FY27 prints, addresses the moat-durability question and the valuation framework on both sides. Bull's structural argument — only listed pure-play in U.S. healthcare BPM with three independent Leader designations and a strategic precedent at 16.3× EV/EBITDA — is genuine; if FY27 Q1/Q2 prints land with margins above 24% and concentration below 60%, much of the bear case loses force. The condition that would shift this verdict from Watchlist toward Lean Long is that print combination — margin ≥24% and top-3 <60% in the same quarter — backed by a clean EQT OFS above $0.53 with mutual-fund absorption; the condition that would shift it to Avoid is the bear's primary configuration (margin <22% and organic CC <12% in the same quarter) or any indication the next OFS clears below $0.44. The durable thesis-breaker is the margin / concentration combination, not any single near-term print; the near-term evidence marker is the pricing and sponsorship of the next EQT block deal, which is highly probable inside 6-12 months.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Moat in One Page

Conclusion: Narrow moat. Sagility has a real, evidenced economic advantage concentrated in one client base and one workflow type. The bull case relies on a regulated-clinical mix shielding the company from AI-driven price compression already hitting the routine end of its book. The advantage is not scale and not brand; it is a regulatory wrapper around an embedded human workflow sold to a small, hard-to-switch buyer pool — and the same arbitrage exists at Firstsource and Genpact, just in lower-margin mixes. A wide-moat rating would require either (a) outcome-based contracting becoming the dominant pricing model, locking in share of payer savings, or (b) top-3 client concentration falling well below 50% while organic constant-currency growth holds in the mid-teens. Neither is yet visible.

The three pieces of evidence that earn the moat designation. First, 24.5% FY26 operating margin against a 13-16% band for diversified peers — a 900-1100 bps gap that is mix-driven, not delivery-efficiency-driven. Second, an 18-year average top-5 client tenure, one named relationship that has just crossed 25 years, and top-3 wallet share falling from 72% in FY23 to 60% in FY26 while the top-3 clients themselves grew at 9.1% constant currency — the combination of "concentration falling while clients still grow" is the single hardest moat signal to fabricate. Third, independent third-party validation: NelsonHall NEAT 2026 Leader in Healthcare Payer Agility and Innovation, Everest PEAK Matrix 2026 Leader in Intelligent Payer Operations, and HFS Horizon Enterprise Innovator in healthcare BPM — three separate analyst grids placing Sagility in the leader quadrant against Genpact, EXL Service, and pre-deal WNS.

The two weaknesses that prevent a wide-moat rating. First, top-3 concentration is still ~60% — a single client renegotiation or insourcing decision could materially impair revenue and break the margin. Second, the regulated-clinical mix that shields the book from AI is roughly 75% of revenue today, but the residual ~25% (routine voice, claims intake, member services) is structurally exposed to per-transaction price compression that is already visible at every BPM peer. The moat protects the core, not the edges.

Glossary used below: switching costs = cost, risk, or workflow disruption a customer faces leaving; intangible assets = brands, certifications, licenses, or data a competitor cannot replicate at will; cost advantage = structural unit-cost gap; embedded workflow = software, processes, or staff inside a customer's day-to-day operations that would be expensive to extract.

Sources of Advantage

Each source is graded High, Medium, Low, or Not proven on company-specific evidence rather than industry strength.

Takeaway: the real moat sits in two boxes — switching costs and intangible assets (certifications + analyst-grid leadership) — both rated High proof. Cost advantage exists but is shared with India-listed peers. Distribution and network effects, often invoked in moat narratives, are absent here.

Evidence the Moat Works

Seven pieces of evidence, drawn from filings, peer benchmarks, and third-party reports. Three support the moat strongly, two with caveats, and two cut against the bull case.

Takeaway: the diversification is real and earned — top-3 share is down 1,250 bps in 3 years while the count of $20mn+ clients has more than doubled. Every one of these "$20mn+ client" wins is a separate switching-cost moat the company is building.

Where the Moat Is Weak or Unproven

Three areas where the bull case rests on assumptions that have not yet been tested.

1. The clinical-mix shield against AI is partial. Roughly 75% of FY26 revenue sits in regulated-clinical and payment-integrity work where CMS rules and licensure requirements protect the FTE pool — but ~25% is routine voice, claims intake, and member services where per-transaction prices are visibly compressing industry-wide. The bull case requires mix-shift to outpace deflation; FY26 shows progress (Synchrony deals signed, BirchAI in nurse-assist roles), but per-transaction compression is moving faster than the disclosed shift. If the routine residual stays at 25% through FY28, ~5-7% per-transaction compression on that quarter absorbs 125-175 bps of group operating margin per year before mitigations.

2. Switching costs are tested by tenure, not by churn. The disclosed 18-year top-5 average tenure speaks to clients who stayed; voluntary churn, win-back, and RFP loss rates are not disclosed. The most plausible source of mass churn is not GenAI but a single top-3 client renegotiating or insourcing — the Optum precedent (UnitedHealth's captive BPM) shows what happens when a payer at scale brings work in-house.

3. Adjusted ROCE of 50%+ masks GAAP ROCE of 13%. Management's "Adjusted ROCE" excludes goodwill and intangibles from the capital base. The GAAP 13% is what the business earns on full capital; the 50%+ describes incremental returns ex-LBO goodwill. A wide-moat business should earn high returns on capital deployed without needing the adjustment. Presentation-driven, not reality-driven (per the Forensic file), but the single most important caveat for any reader anchoring on headline ROCE.

Moat vs Competitors

The peer set is anchored on NelsonHall NEAT 2026 vendors and BPM majors with named healthcare segments. The right competitors are not Indian IT services (TCS, Infosys) but US-listed BPM with healthcare verticals plus Firstsource as the local valuation anchor.

Takeaway: Sagility's strongest moat dimensions are switching costs and intangibles, where it scores 4/5 against a peer set in which only Capgemini-WNS matches both. It is structurally weaker on scale economies and absent on network effects. The Capgemini-WNS combination is the only peer that matches Sagility on both switching costs and intangibles while also having scale on its side — which is why competition flagged it as the single largest 24-month threat.

Durability Under Stress

A moat only matters if it survives stress. Six scenarios that test whether the advantage holds.

The uncomfortable scenario is #2 paired with #3 in the same year. A top-3 client price renegotiation combined with accelerating GenAI deflation on the routine 25% would test the moat at the operating-margin line in a way FY22-FY26 history has not. The other four stress cases are individually manageable; this combination would not be.

Where Sagility Ltd Fits

The moat is not evenly distributed across the company. It sits in identifiable parts of the book.

Where the moat is strongest. Clinical services, payment integrity, risk adjustment, and Star ratings — roughly 75% of FY26 revenue — is where regulated-workflow, certification, and embedded-staff moats compound, the part earning 24.5% margin and surviving the GenAI deflation case. It is also where Synchrony Lifecycle outcome-based contracting starts to capture share of payer savings rather than billing FTE hours; scaling Synchrony is the path that would widen the moat from "narrow" toward "wide" over 3-5 years.

Where the moat is weakest. Routine voice, claims intake, member services, and provider-credentialing — roughly 25% of FY26 revenue. Per-transaction voice prices are estimated to fall 30-50% over five years; this is where private peers (Omega, GeBBS, IKS) win on price and where GenAI productivity gains are already showing in EXL Code and Genpact Cora deployments. Mix-shift away from this work is the single most important strategic question.

Geography. The moat is US-only. UK and Philippines revenue (~5% combined) is an attached optionality, not a separate moat. The cost-base advantage is dominated by India (~55% of headcount) and Philippines (~30%); Jamaica and Colombia near-shore are growing but small.

Client mix. Top-3 (Aetna, Anthem/Elevance and a third unnamed payer based on disclosed wallet share) carry the deepest switching-cost moat — these are the 18-25-year tenured relationships. Top-4 through top-9 (each $20mn+) are newer, broader, and individually less embedded. BroadPath-acquired mid-market payers (~30 names) are the youngest cohort; switching costs are real but shallower because integration depth has not yet accrued.

Takeaway: the moat is concentrated in payment integrity, utilization management, and risk adjustment — together ~40% of FY26 revenue and the highest-margin parts of the book. The "narrow" rating reflects that the other 60% sits between medium and low on moat strength.

What to Watch

Six signals, deliberately measurable in either Sagility's quarterly KPI table or in third-party reports. Each tells you faster than headline revenue whether the moat is widening, holding, or eroding.

The first moat signal to watch is top-3 client concentration in the quarterly KPI table. Disclosed every quarter, hardest to fake, and the tail risk mapping most directly to a thesis-breaking outcome — a top-3 client renegotiation. Analyst grids, Synchrony mix, and Capgemini-WNS bookings all move on multi-quarter or annual timescales; top-3 concentration is the one number that can tell you the moat is changing inside ninety days.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Forensic Verdict

Sagility's reported numbers pass the most important forensic stress-tests: five-year operating cash flow runs at roughly 1.8x net income, accruals are persistently negative (CFO above NI), and there is no restatement, auditor change, regulatory enforcement, or short-seller dossier on the public record. The accounting risk that does exist is structural — a giant goodwill/intangible block from the 2022 HGS carve-out, an aggressive adjusted-EBITDA stack that strips out earn-outs, SARs, forex and "exceptional" labour-code charges, and a control structure where EQT-owned Sagility B.V. still controls the company, prices the share-based pay, and has been the active seller of stock. The single data point that would most change the grade is a reversal in cash conversion — if CFO/NI falls below 1.0x while DSO climbs above 95 days, the "earnings quality is conservative" thesis breaks.

Grade: Watch (21-40). The verdict is "underwrite the structure, trust the numbers" — not the other way round.

Thirteen-Shenanigan Scorecard

Breeding Ground

The structural breeding ground is elevated but mitigated. Sagility is a recent (Nov-2024) IPO carve-out from Hinduja Global Solutions, still controlled (50.95%) by EQT-owned Sagility B.V., and the parent has been actively selling down. The board has more independence than typical promoter-controlled Indian listings (5 of 9 directors independent), the auditor is BSR & Co LLP (KPMG India network) with no qualifications, and the internal auditor is EY — all standard institutional quality. What we cannot ignore: the parent prices, awards and settles share-based pay outside the listed entity, the chairman is a parent-appointed non-independent, and management compensation is heavily weighted to variable pay.

The breeding ground is where Sagility looks materially different from a regular listed Indian IT-services peer. Institutional protections (Big-4-affiliate auditor, independent board majority, no auditor change, clean Sec 143(12) report) keep the risk in yellow rather than red, but three caveats matter when reading the financials: (1) the parent still sets the rules on share-based pay, (2) EQT has been an active seller and likely remains one, and (3) the P&L sits on top of $700M+ of acquisition-sourced goodwill that did not arise inside the listed entity.

Earnings Quality

Earnings quality is good in substance but optically inflated by an aggressive adjusted stack. The four most important tests pass: (a) operating margins are stable at 23-25% across five years, (b) reported PAT is consistently lower than CFO, (c) FY25 net income jumped 136% but the entire jump is explained by lower amortisation (HGS intangibles fully amortised) and lower interest (promoter debt repaid), and (d) FY24's 6% effective tax rate normalised to 25-29% by FY26 without any reserve release lifting reported PAT. The problem is what management highlights — Adjusted PAT margins run 280-500 bps above GAAP because they strip out items that recur (earn-outs, SARs, intangible amortisation, exceptional labour-code charges).

Revenue, receivables, and unbilled

DSO is the single most-watched accounting metric in BPO/BPM. It dropped to 83 days in FY25 (collections tightened ahead of and post-IPO) and rose to 93 days in FY26. Management attributed the Q4 FY26 climb to "a reclassification from unbilled to financial liabilities" worth about 4 days, plus seasonal H2 mix from the AEP/OE peak. Both explanations are plausible, but a mid-year reclassification of DSO definition belongs on the watch list — Genpact and EXL did not need a reclassification footnote to explain their FY26 DSO trajectory.

Margins, amortisation roll-off, and tax volatility

Two earnings-quality points jump out. First, the post-amortisation margin nearly doubled from FY24 (8.5%) to FY26 (17.7%) — not from operating improvement but because the HGS carve-out intangibles fully amortised by FY24 and acquisition-related intangibles are smaller. This is mechanically correct, not a shenanigan, but it means FY25-26 GAAP earnings growth is partly a base-effect of amortisation roll-off, not pure operating leverage. Second, the FY24 6% effective tax rate is an outlier — a deferred-tax credit and India employment-generation incentive temporarily lifted net income. The FY24 PAT base is therefore not a clean comparator for FY25's 136% growth.

Soft assets and goodwill weight

The "Fixed Assets" line in Indian reporting includes goodwill and other intangibles. At FY25, goodwill alone is ~$700M ($605M from HGS, $57M from DCI/BirchAI/BroadPath, $44M from FX translation), against total assets of $1.28B. The balance sheet is more than half goodwill. This is not a red flag in itself — it correctly reflects the purchase price paid by EQT to acquire the healthcare BPM business from HGS in January 2022 — but it means GAAP ROE/ROCE will permanently look low, which is exactly why management built "Adjusted ROCE" excluding goodwill and reports 50%+ versus 13% on the GAAP basis.

Cash Flow Quality

Cash flow quality is the strongest piece of the forensic picture. CFO has tracked or exceeded reported operating profit for four consecutive years (99%, 101%, 106%, 90% cash conversion), there is no evidence of receivable sales / factoring / supplier finance, and acquisitions have been cash-funded from operations rather than from working-capital lifelines. The number to underwrite is whether 90% cash conversion in FY26 (down from 106%) marks a return to baseline or the start of a slide — management said FY26's lower conversion reflects a one-time FY25 India tax refund that did not repeat, higher non-cash forex gains, and the working-capital absorption of BroadPath.

The shrinking CFO/NI ratio is good news disguised as bad news: net income is rising faster than CFO because the HGS amortisation that depressed reported earnings has run off. Pre-FY25, every dollar of net income generated 4-5 dollars of CFO because amortisation was the dominant non-cash item. FY26's 1.30x is approaching a "normal" services-company ratio. A move below 1.0x would be the first genuine red flag in this stack.

Acquisition-adjusted free cash flow

Estimates of acquisition outflow are derived from disclosed deal values (DCI April-2023, BirchAI March-2024, BroadPath ~$60M January-2025 plus pending HGS consideration) — exact splits across years are approximate. After accounting for acquisitions, FY25's standout $128M reported FCF shrinks to ~$36M — still positive, but a fraction of headline. Sagility self-funded BroadPath without raising debt, which is genuinely impressive; readers underwriting "self-funded compounder" should still apply this haircut.

Working capital contribution

The cash-flow statement does not break out working-capital movements in the data we have access to, but the DSO trajectory (83 → 93 days FY25→FY26) implies a working-capital headwind of ~$24M in FY26 — i.e., absent the seasonal-mix and reclassification effect, headline CFO would have been higher. No evidence of payables stretching (CFO did not get an obvious lift from suppressed inventory or extended payables), but the absence of a detailed working-capital schedule is itself a disclosure gap.

Metric Hygiene

Metric hygiene is the weakest area of the forensic file. Sagility runs a five-step adjusted stack — Adjusted EBITDA, Adjusted PAT, Adjusted EPS, Adjusted ROCE, and constant-currency revenue — and each adjustment is individually defensible but the cumulative effect is a 280-500 bps overstatement of margin versus GAAP. The most aggressive single adjustment is Adjusted ROCE at 50%+, which excludes goodwill and intangibles from the capital base; the GAAP equivalent is ~13%. Management discloses the calculation in footnotes, but the headline is the 50% number, not the 13% one.

The PAT gap narrows from 760 bps in FY24 to 280 bps in FY26 as the amortisation that adjustments strip out mechanically rolls off. On current trajectory, the GAAP-vs-Adjusted gap could fall under 200 bps by FY28, making the adjusted stack less load-bearing. Today it still matters: anchoring on 15.7% Adjusted PAT versus 12.9% GAAP changes what a peer-multiple application implies for fair value.

What to Underwrite Next

The forensic risk here is real but bounded, and translates to a valuation haircut (anchor on GAAP PAT, not Adjusted) and a position-sizing limiter (until cash conversion stabilises), not a thesis breaker. Concretely:

Track every quarter:

1. DSO ex-reclassification. Sagility moved ~4 days from unbilled to financial liabilities in Q4 FY26. The Q1 FY27 print should let analysts re-compute clean DSO. If DSO ex-reclass exceeds 95 days, the H2-seasonality story breaks.
2. CFO/NI conversion. FY26 came in at 1.30x (down from 2.25x). 1.0x is the line in the sand. Below that, the company is generating accruals, not cash.
3. Adjusted ROCE versus GAAP ROCE. Adjusted is 50%+, GAAP is 13%. Watch whether management continues to lead with the adjusted figure as the goodwill block compounds with more deals.
4. Earn-out recurrence. DCI, BirchAI and BroadPath earn-outs are still being expensed. Each future M&A deal adds another earn-out stream that will be tagged "non-recurring" again. Count the cumulative "non-recurring" earn-out add-backs over a five-year window — that is the recurring cost of the M&A strategy.
5. Promoter (Sagility B.V.) sell-down. EQT moved from 82.39% to 50.95% in one fiscal year. Further selling is likely; alignment between selling promoter and minority shareholders weakens as the holding shrinks.

What would downgrade the grade to Elevated (41-60):

• DSO above 100 days without a clear collection issue
• CFO/NI below 0.8x for two consecutive periods
• A new "exceptional" line item that reverses last year's exceptional
• An auditor change, late filing, or material weakness disclosure
• Reduction in independent director count or audit committee composition

What would upgrade the grade to Clean (0-20):

• Two consecutive years of cash conversion above 95% post-amortisation roll-off
• Convergence of Adjusted PAT to within 100 bps of GAAP PAT (likely by FY28 on current trajectory)
• Completion of promoter sell-down and stabilisation of share register
• Disclosure of receivable composition (billed vs unbilled vs reclassified) on a comparable historical basis

Bottom line: the accounting risk at Sagility is presentation-driven, not reality-driven. The cash is there, the auditor is clean, the customer base is verifiable, and the principal issues are an aggressive adjusted-metric stack and a balance sheet weighed down by goodwill that arose before the company was listed. Anchor on GAAP, consider a valuation haircut for the adjusted-stack optics and promoter overhang, and re-test next quarter once the DSO reclassification has comparable history. Watch, not avoid.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Governance Grade: B−

Sagility passes the basic SEBI tests — 5 of 9 directors are independent, committees are properly constituted, and disclosure quality is clean — but the company is owned by a private-equity exit machine. EQT/Sagility B.V. has already cut its stake from 95%+ pre-IPO to 50.95% in eighteen months, the IPO and both subsequent sell-downs raised zero primary capital, and no insider other than the promoter owns disclosed equity. The board is credentialed and the CEO is competent; the problem is alignment, not integrity.

---

1. The People Running This Company

Five names matter. The rest is depth.

The CEO is a known quantity. Ramesh Gopalan ran this exact business when it sat inside Hinduja Global Solutions, was carved out alongside the asset in the 2021 EQT transaction, and was formally elevated from interim leadership to MD/Group CEO on 24-Jun-2024 — five months before listing. That is short tenure as a public-company CEO but long tenure on the underlying business. There are no disclosed prior controversies, regulatory actions, or litigation against him in the data set.

The two promoter-nominee directors — Mahtani (BPEA) and Gopalakrishnan — are present to represent EQT's economic interest, not to challenge it. They take no remuneration and will rotate off as EQT exits. The independence calculus on this board therefore depends almost entirely on the five formally independent directors.

---

2. What They Get Paid

The structure is unusual for a recently-IPOed Indian IT/BPM company: pay is 50/50 fixed-and-variable cash, with no listed-stock equity granted to the CEO in FY25. That is a one-year artefact — the company listed in Nov 2024 and the ESOS 2026 scheme (proposed May 2026 board meeting, up to 3.30% dilution subject to shareholder approval) will be the first material public-market equity instrument.

Cash pay is reasonable. $0.80M for the CEO of a ~$0.6B-revenue listed services company is below Coforge, Persistent, or Mphasis CEO pay and broadly in line with mid-cap IT-BPM benchmarks. The 220× pay-ratio to median employee is high for India but is mechanical — the median is dragged down by a 46,000-strong agent workforce in India and the Philippines (median compensation ~$3,654 per year).

The flag is timing: the CEO's first equity grant will be priced after EQT has continued to exit and the stock has potentially repriced. Watch how the ESOS 2026 strike is set and whether vesting includes performance hurdles or pure time-based vesting.

---

3. Are They Aligned?

Three pieces: an ongoing private-equity exit, no executive personal stake, and shareholder-friendly capital return so far.

Ownership: an organised PE exit

Insider buying / selling: silence except for the promoter

Trendlyne SAST/PIT filings show no executive or director own-account purchases or sales since 2015 under SEBI PIT regulations. The only insider activity on record is Sagility B.V.'s two sell-downs above. No executive has bought a single share in the open market post-IPO.

That silence cuts both ways. No executive is dumping shares; but no executive has meaningful personal capital at risk either — they collect salary and bonus, and will collect ESOPs once the 2026 plan is approved. There is no founder-style alignment.

Dilution and equity grants

The 3.30% ESOS pool is large for a single grant but reasonable as a multi-year reserve for a 46,000-employee company. Until vesting and strike-pricing details are filed, it is the single most important governance disclosure to watch through 2026-27.

Related-party behaviour

Sagility B.V. (Netherlands, EQT-owned) is the promoter; Sagility Health LLC (US) and other subsidiaries are nested under it. The standard RPT risks in this structure are management-fee leakage, trademark-license charges, and shared-services cross-bills. None of these surfaced as material in the disclosures or in independent commentary through Mar-2026. The Audit Committee is independent-majority and the policy was updated to the post-1-Apr-2023 SEBI LODR standard.

Capital allocation

Capital allocation is shareholder-friendly in stated intent: deleverage, modest dividend ($0.0018 total FY26 per share), continued tuck-in acquisitions. The CEO has been explicit that growth in payouts will come "though there's no firm commitment." Total FY26 cash returned to shareholders is modest (~0.4% yield at current price) but defensible while debt is still being retired.

Skin-in-the-game score: 5/10

The 5/10 reflects a control-shareholder that is genuinely aligned today but on a stated path to becoming an ordinary minority. The score will mechanically drift down each time EQT places a block, unless and until a domestic strategic or insurer takes a 5%+ position as anchor.

---

4. Board Quality

Real, not just formal, independence. Of the five independent directors:

• Dr. William Winkenwerder Jr. brings the strongest single credential: ex-Assistant Secretary of Defense for Health Affairs, ex-CEO of Highmark, and a long career in US payer governance. For a company whose entire revenue base is US payers, this is the single most valuable seat.
• Ginger Dusek adds US payer operational expertise from inside the industry.
• Anil Chanana and Venkat Krishnaswamy carry the finance/audit credentials; Chanana's profile aligns with finance-leadership tenure at a large Indian IT services firm.
• Dr. Shalini Sarin rounds out the board with sustainability and policy experience.

The principal gap is technology and cybersecurity. For a company selling generative-AI services into HIPAA-regulated US payer workflows, a dedicated tech/data-protection independent voice would meaningfully strengthen the board. Current expertise on this dimension is thin.

The principal strength beyond independence is committee composition: Audit and Nomination/Remuneration are independent-majority and chaired by independents — not always the case in promoter-controlled Indian companies.

One female independent director (Dr. Sarin) — meets but does not exceed the SEBI minimum. A second would be a reasonable expectation for FY27 given the board's stated emphasis on diversity in the corporate governance report.

---

5. The Verdict

Grade: B−. Properly constituted board, credentialed independents in the right domains, clean RPT and disclosure track record, sensible cash compensation, and shareholder-friendly capital allocation. The deductions are real but specific.

Strongest positives

• Independent-majority Audit and NRC, chaired by independents.
• A genuinely useful payer-domain independent in Winkenwerder.
• No insider selling outside the promoter; no executive perks, related-party leakage, or compliance flags surfaced in the data set.
• CEO is the operator who built the business, not a hired manager.

Real concerns

• The promoter is a PE fund whose exit is the operating model. Two block deals in twelve months took its stake from 82% to 51%. The third is a matter of when, not if.
• No executive owns disclosed listed equity. ESOS 2026 has not yet been structured.
• Board tech / cyber expertise is thin for a company selling GenAI into HIPAA-regulated US payer workflows.
• The CFO transitioned during the sell-down window — operationally minor, but a continuity question.

What would move the grade

• Upgrade to B/B+ if the ESOS 2026 strike is set at a meaningful premium with performance-vesting tied to revenue or margin, and at least one executive starts buying on the open market.
• Downgrade to C+ if the next EQT exit is followed by no anchor replacement, a related-party transaction surfaces, or the ESOS is granted at a deep discount without performance hurdles.

The pivotal variable is what replaces EQT. A 5%+ position taken by a domestic strategic, a US healthcare partner, or a long-term institutional anchor in the next OFS would strengthen the alignment story. If the next block distributes to passive funds, the board becomes the sole governance check — the directors above are credentialed enough, but the company is still too young to know how that holds up under stress.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Story Sagility Has Told

Sagility's listed life began in November 2024 with a single promise: a healthcare-only operator that compounds in the low-to-mid teens at a 24–25% adjusted EBITDA margin. Across seven earnings calls and an Investor Day, the team has beaten that bar every quarter and quietly enlarged what they are willing to be measured on. The narrative has rotated from "stable carve-out" to "BroadPath-fuelled mid-market expansion" to "Synchrony-led managed-services transformation," each pivot raising the perimeter without resetting the floor. Credibility has strengthened, but the team has not yet been tested on the harder promise — that AI will be a net tailwind rather than the slow drip of cannibalisation everyone now agrees is coming.

Who is running the story

Ramesh Gopalan has run the platform since EQT carved it out of Hinduja Global Solutions in January 2022, and most of his operating bench transitioned with him. The "company" is only four years old; the operating muscle is twenty-five. The current strategic chapter — pure-play U.S. healthcare BPM under EQT, then under public-market scrutiny — also dates from 2022. The business that current leadership inherited was already high-quality on the operational metrics (sticky 17-plus-year payer relationships, top-quartile CSAT, 24%+ margins) — but came loaded with leveraged-buyout debt and roughly $683 million of goodwill / intangibles that still distort headline ROE today.

1. The Narrative Arc

The chapters fall out cleanly. 2022–2024: private capability-building under EQT — Devlin (payment integrity) and BirchAI (GenAI) bolted on. November 2024: IPO with a tight thesis — stable double-digit growth on a 17-year client book. January 2025: BroadPath widened the thesis — the first acquisition that wasn't about capability but clients, adding 30 mid-market payers and forcing management to defend deliberate margin dilution. Mid-2025 onward: AI conversation matured from "we have BirchAI use cases" to PMPM and gain-share constructs. March 2026 Investor Day: rebranded into "Synchrony" — outcome-based managed services with bundled tech — and defined the next chapter as cost takeout for payers under MLR pressure, with Sagility taking accountability for the outcome rather than billing for the hour.

2. What Management Emphasised — and What They Quietly Stopped

Three patterns are worth pulling out of the grid.

AI has been everywhere from day one — but the shape of the AI message changed twice. At IPO it was a defensive answer to "will GenAI cannibalise you?" By Q2 FY26 it was a commercial construct: management spent half the prepared remarks walking analysts through PMPM and gain-share deals where AI agents are billed at a fraction of human rates. By Q4 FY26 it was rebranded as "Synchrony" and positioned as the growth lever, with AI explicitly described as a "force multiplier, not a disruptor."

"BPaaS" died and "Synchrony" was born from the same idea. At the first earnings call after IPO, Ramesh told investors BPaaS bundled deals were "still work in progress." For the next four quarters BPaaS was barely mentioned. At the March 2026 Investor Day, exactly the same idea — bundled tech-plus-services, outcome-based pricing — was relaunched under the Synchrony brand with three concrete sub-products (Medicare enrolment, claims lifecycle, payment integrity). The pivot wasn't a u-turn; it was a quiet rebrand and a productisation push.

Two themes have quietly faded. Captive / GCC competitive threat got a careful response at IPO; by Q2 FY26 it had become a revenue source — Sagility was disclosed as helping a client set up a BOT-model GCC. And provider-segment growth was front-of-mind in the early calls (33–38% YoY against a small base), but by Q3-FY26 it had stalled at ~$20M/quarter for four consecutive quarters and management acknowledged it only when pushed.

3. Risk Evolution

The risk register evolved more sharply than the growth story. At IPO, analysts pressed hardest on Trump policy uncertainty and the captive-GCC threat. By FY25 close, those faded and a new dominant risk emerged: Medicare Advantage utilisation pressure — first observed in calendar 2024 prints from United and others, then absorbed into the narrative as a demand catalyst (clients under MLR pressure outsource more). By FY26 close, the slate shifted to U.S. policy items: the One Big Beautiful Bill cutting Medicaid funding, ACA subsidy expiry, the HIRE Act's 25% offshoring excise, and H1B changes. Each was systematically explained-then-dismissed in the same call, citing low exposure or low pass-through risk.

What's not on the heatmap matters too. The HGS carve-out's legacy litigation with Synergy Global Outsourcing — potential damages up to $115.9 million per the FY25 annual report — has not been mentioned in a single earnings call. It is indemnified by HGSI and covered by a bank guarantee, but its absence from the spoken narrative is striking for an exposure of that size.

4. How They Handled Bad News

Sagility has not had a true blow-up to manage, so this section is about moderate surprises and whether management framed them honestly.

Two patterns stand out. The team is unusually disciplined about not over-claiming on positive surprises — Q3 FY25's 31.4% margin was an obvious chance to raise the steady-state band, but management explicitly walked it back to 24–25% on the same call and explained the bridge. That credibility purchase paid off later: when guidance was raised in Q2 FY26, Q3 FY26, and again at Q4 FY26, analysts took it at face value.

The two soft spots are both about quiet walk-backs. The debt-repayment timeline slipped a full year (from end-FY26 to end-FY27) without ever being pre-flagged as a slip — it surfaced only in the changing schedule slide. And the CFO transition between Sarvabhouman Srinivasan and Srinivas Mattapalli at the May 2026 call (with Abhishek Kayan stepping in as Deputy CFO during Q3 FY26) was handled with a one-line introduction and zero discussion of why or how. For a public company in its first 18 months, that is the only meaningful governance opacity in the file.

5. Guidance Track Record

Credibility score: 8 / 10.

The team has done the rarest thing for a recently-IPO'd Indian mid-cap — raised growth guidance three quarters in a row and delivered margin above the upper bound of every band set. The only outright miss is the debt-repayment slip from end-FY26 to end-FY27, tied to RBI external-commercial-borrowing minimum-tenor rules rather than business deterioration. Why not a 9 or 10: (a) FY27's "low double-digits" guide bakes in 200 bps of AI cannibalisation vs the 1.5% disclosed at IPO — the first time the AI math has moved against them; (b) the CFO transition was handled with no narrative; (c) Synchrony/BPaaS has been discussed across two fiscal years with limited revenue disclosure.

6. What the Story Is Now

By the end of FY26, Sagility tells a very different story than the one in its prospectus. The IPO pitch was "stable carve-out compounder running a 17-year client book at 24–25% margins." The current pitch is closer to "healthcare-only transformation partner that commits to client cost takeout — funded by Sagility's own balance sheet — in exchange for end-to-end scope expansion." That is a bigger pitch with a larger TAM and a longer sales cycle.

What has been de-risked since the IPO:

• The seasonality has been re-explained, accepted, and now expected. Q3-Q4 OE-linked revenue rose from ~3% of the year (pre-BroadPath) to ~6% in FY26, and analysts no longer model it as noise.
• BroadPath integration risk is largely behind them. Margin dilution came in at the low end of the disclosed range (~110 bps vs 120–150 bps promised). Cross-sell pipeline is open if slower than hoped.
• GenAI as a binary threat is off the table. Management has shown — with three concrete deal constructs and 32 deployed use cases across 10 clients — that they can monetise AI through gain-share and PMPM rather than just absorb the cannibalisation.
• Client concentration has materially eased. Top 3 fell below 60% of revenue and clients above $20M in size doubled from 4 (FY23) to 9 (FY26).

What still looks stretched:

• Provider segment has flat-lined around $20M/quarter for four consecutive quarters. Management acknowledges it only when pushed. For a segment they promised to "grow aggressively," that is the story's softest spot.
• Synchrony / managed-services revenue is not yet disclosed as a line. At the Investor Day they would not quantify what share of revenue managed services represents — only that pipeline is roughly $570M TCV. Until that number appears, the transformation pivot is a promise.
• AI cannibalisation has been re-rated upward — from ~1.5% to "2%+ in FY27" — and management is preparing investors for it to climb further. Growth guidance for FY27 (low double-digits) implicitly bakes this in.
• The ROCE story remains accounting-dependent. Reported ROE is in single digits because of the LBO-loaded goodwill; the 50%+ "adjusted ROCE" requires the analyst to strip out goodwill and intangibles from the carve-out. This is mathematically defensible but requires investor trust.

What the reader should believe:

• The team can compound the existing book at low-double-digits constant currency with margins in a 24–25% band. That's been earned with seven quarters of delivery.
• Cost-pressured payers are real, persistent customers for what Sagility does. MLRs in the high 80s/low 90s aren't going away in 2026.
• BroadPath's mid-market client list is being mined — slowly but with real proof points.

What the reader should discount:

• The Synchrony / managed-services TAM claims until they show up as a disclosed revenue line.
• The "double-digit growth in top 5 clients" durability — top-5 growth has slowed from 17%+ at IPO to 11.7% in FY26, and the FY27 guide implies it slows further.
• Any extrapolation of the FY25–FY26 forex-driven margin expansion. Management itself has flagged that the upper-end of the FY27 margin band is FX-dependent — i.e. if the rupee stops depreciating, margins compress back to the lower end.

---

Financials — What the Numbers Say

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Sagility is a US-payer-focused healthcare BPM business carved out of Hinduja Global in 2021, listed in India in November 2024, and reporting in INR even though most revenue is invoiced in US dollars. Read every number through that lens — the rupee top line is partly an FX statement.

1. Financials in One Page

Sagility delivered $767M of revenue in FY26 (up 29.1% YoY), a 24.5% operating margin, and $108M of free cash flow. Borrowings have fallen from $632M at carve-out (FY22) to $118M at FY26, ROCE has stepped up from 5% to 13.4%, and the stock trades at roughly 19.8× trailing earnings — a multiple that already pays for the visible operating leverage. The single financial metric that matters most right now is operating margin durability through FY27: the bull case rides on sustaining ~24%-25% EBITDA margins while revenue compounds in the high-teens, and the recent quarterly print shows margin progress slowing, not accelerating.

Glossary in one place. Operating margin = operating profit ÷ revenue. ROCE (Return on Capital Employed) = EBIT ÷ (equity + debt) — measures how productively the whole capital base is used. Free Cash Flow (FCF) = cash from operations minus capex; it is the cash actually available to repay debt, pay dividends, or buy back stock. Net Debt / EBITDA tells you how many years of operating cash earnings it would take to repay debt net of cash on the balance sheet.

2. Revenue, Margins, and Earnings Power

Sagility's revenue is over 90% US healthcare payer outsourcing — claims administration, member services, clinical reviews, payment integrity — invoiced in USD and translated to INR for reporting. That gives the top line a structural tailwind whenever the rupee weakens against the dollar, and the rupee weakened roughly 11% across FY22-FY26 (USD/INR moved from ~75 to ~94). Some of the reported growth is real volume; some is FX.

How to read this. FY22 is an 8-month stub because the legal entity was carved out in August 2021; ignore it for like-for-like growth comparisons. From FY23 to FY26, revenue compounded at roughly 14% per year in USD terms — strong for a labour-arbitrage BPM, and stripped of rupee depreciation. (Reported INR growth was closer to 19% per year; the gap is FX.) The acceleration to +18% in FY26 (USD) reflects new client wins, the BroadPath acquisition, and a benign US payer outsourcing demand cycle.

Operating margin has stayed in a tight 23%-25% band — impressive for a people-heavy services business — but the real earnings power story is in the gap between operating margin and net margin. Net margin expanded from -0.5% to 12.9% over four years because interest expense fell from $86M (FY22) to $11M (FY26) on a much larger revenue base, depreciation/amortization moderated as the goodwill amortization layer worked down, and the effective tax rate normalised. Interest cover (EBIT ÷ interest) widened from roughly 3× to 18× — a balance-sheet story masquerading as a margin story.

Recent Quarterly Trajectory

Three points jump off this chart. First, the revenue step-up in 3Q26 ($219M versus $187M the prior quarter) is the BroadPath acquisition flowing through, not pure organic growth. Second, operating margin compressed to 22.5% in 1Q26 — a reminder that wage hikes and onboarding new accounts can absorb a full quarter of operating leverage. Third, 4Q26 margin of 24.0% is below the 3Q26 peak of 25.9% even on a higher revenue base — the kind of step-back that drove the post-earnings stock decline. Earnings power is improving, but not in a straight line, and the marginal quarter no longer surprises to the upside.

3. Cash Flow and Earnings Quality

Earnings quality is the cleanest part of the Sagility story. Free cash flow is the cash a business generates after paying for working capital and capital expenditure — it is what is left for debt repayment, dividends, buybacks, and acquisitions. For four consecutive years Sagility has converted more than 95% of operating profit into cash from operations.

Net income is substantially below operating cash flow because depreciation and amortization of carve-out goodwill is a large non-cash charge ($52M in FY26 on its own). That is exactly the right shape for the business model: the goodwill was created in the 2021 buyout from Hinduja Global, but the cash generation belongs to the operating company. FCF stepped down in FY26 ($108M versus $128M in FY25) for two reasons — working capital absorbed $12M as receivables stretched with the new BroadPath book, and capex rose roughly 30% to support delivery centre expansion. Neither is alarming. Both are worth tracking.

4. Balance Sheet and Financial Resilience

The balance sheet was the major risk at carve-out and is now the major signal of improving quality. Sagility was loaded with $632M of debt to finance the 2021 acquisition; four years of cash generation and roughly $250M of fresh equity raised at IPO have brought borrowings down to $118M.

The change in financial resilience between FY22 and FY26 is the biggest single fact in this page. Net Debt / EBITDA fell from 1.4× to 0.1× — Sagility is effectively unlevered. Interest coverage (EBIT divided by interest expense — how many times over a company can pay its interest bill from operating profit) widened from 3× to nearly 18×, the range associated with investment-grade quality regardless of formal rating. There is no near-term refinancing risk, no debt-covenant pressure, and meaningful room to either redeploy cash into M&A or step up shareholder returns.

The balance sheet gives management three optional moves: (1) clear the remaining $118M of debt and run net-cash; (2) raise the dividend payout from the current 8% to something closer to peer norms of 20%-30%; or (3) make another BroadPath-sized tuck-in. The capital allocation choice from here is more interesting than the balance-sheet risk.

5. Returns, Reinvestment, and Capital Allocation

Returns on capital — the truest measure of business quality — have compounded as the goodwill drag has worked off and operating leverage has scaled.

ROCE of 13.4% is a respectable mid-teens number for a labour-arbitrage services business, but well below the 25%-30% the best Indian IT/BPM names achieve. The reason is the goodwill in the asset base — almost $997M of fixed assets are dominated by acquired intangibles, not operating equipment. If you strip goodwill out, ROCE on tangible operating capital is materially higher (likely 35%-40%); the reported number understates underlying capital productivity but correctly reflects the price paid for the carve-out.

The capital allocation story is straightforward: from FY22 to FY25, every spare dollar went to debt repayment; in FY26, with the balance sheet largely cleared, management redirected cash into the BroadPath acquisition (estimated ~$80M based on cash-flow-from-investing) and initiated a maiden dividend (8% payout ratio, yielding roughly 0.12% at current price). The dividend is symbolic, not material. The acquisition is the live signal — if BroadPath delivers, the next move could be a larger consolidation play.

Share count is a non-issue because Sagility raised roughly $250M of fresh capital at its November 2024 IPO at $0.32 per share and has not done any further dilutive issuance. The 4.68 billion shares outstanding (after IPO) are the steady-state share count.

EPS has grown at a 33% CAGR since FY23 in USD terms; book value per share has grown more than four-fold; FCF per share is up roughly 20%. Management is compounding per-share value, not just absolute size — and they are doing it without dilution.

6. Segment and Unit Economics

Sagility does not publish formal operating-segment financials. The disclosed split is between Core Benefits Administration (claims processing, member services, payment integrity for US health insurance payers — roughly 88% of revenue) and Clinical Services (utilization review, care management, clinical document improvement — roughly 12%). Geography is concentrated: more than 95% of revenue is from US customers; the residual is from UK and Philippines clients.

The segment story matters because the clinical-services book is where the moat sits — it is sticky, regulated, and grows with payer focus on prior authorization and utilization controls. The core benefits book is a higher-volume, lower-mix-margin business that is more exposed to payer concentration and contract renegotiation risk. Within the disclosed envelope, every margin step-up Sagility delivers from here is likely to come from mix shift toward clinical services, not from the BPO core.

7. Valuation and Market Expectations

This is where the investment debate sits. The stock has gone from $0.31 at IPO (Nov 2024) to a 52-week high of $0.61 and back to $0.42 — round-tripping the entire post-listing rally. At $0.42, the market is pricing 19.8× trailing earnings and roughly 17× EV/EBITDA on a business growing 29% with a 24%-25% operating margin.

The de-rating from a peak P/E of about 38× to 19.8× is the story of the past 18 months — earnings have caught up to the share price faster than the share price has fallen. The setup is constructive: the stock is flat while the underlying business compounds. P/E now sits below FSL (India's closest BPM peer, around 22×) and roughly in line with US BPM benchmarks adjusted for the India listing premium.

Against $0.42, the base case implies roughly 40% upside over two years, the bull case roughly 140%, and the bear case roughly 12% downside. The asymmetry leans positive, but valuation is no longer the easy "deep value" setup of a year ago — further upside hinges on either margin expansion (which slowed in 4Q26) or a re-rating back toward the IPO peak (which depends on consensus believing high-teens growth is durable).

EV/EBITDA cross-check

At $0.42 and 4.68bn shares, market cap is $1,973M. Net debt of roughly $74M (borrowings $118M less ~$43M cash) takes enterprise value to roughly $2,047M. FY26 EBITDA is approximately $240M (operating profit of $188M plus depreciation/amortization of $52M). That puts EV/EBITDA at 8.5× — well below US-listed BPM peers EXLS (17.9×) and Genpact (9.6×), and roughly in line with FSL on a normalised basis.

8. Peer Financial Comparison

Sagility has the highest operating margin in the cohort by a wide margin (24.5% versus 14.8%-16.3% for healthy peers), the lowest net leverage, and the second-fastest revenue growth — yet trades at a meaningful discount to EXLS and a modest discount to Genpact on EV/EBITDA. The most relevant transaction multiple is the Capgemini–WNS deal at roughly $3.3bn EV on FY25 revenue of about $1.3bn (~2.5× EV/Sales); Sagility's current EV is about 2.7× FY26 sales — the same range. Either Sagility re-rates toward EXLS or US BPM peers de-rate toward Sagility; either path argues against shorting Sagility on absolute valuation.

The one peer that needs no defence is FSL — same FY-end, same INR cost base, same India listing — and Sagility beats it on operating margin (24.5% vs 16.3%), ROCE (13.4% vs ~17% reported but inflated by leverage), and growth (29% vs 20%). The Sagility discount to FSL on P/E is therefore the cleanest mispricing signal in the page.

9. What to Watch in the Financials

What the financials confirm. A genuinely high-quality services business, with peer-leading margins, peer-leading cash conversion, peer-leading balance-sheet flexibility, and a per-share value-compounding profile since IPO.

What the financials contradict. The market's de-rating from 38× to 20× P/E is hard to reconcile with the underlying numbers — margins held, growth accelerated, debt fell. The stock has acted as if the operating story has cracked; the financials, so far, do not show that.

The first metric to watch is operating margin in 1Q FY27. Margin holding at or above 24% on constant-currency revenue growth of 14%+ would be the setup for a re-rating back toward EXLS multiples (25×+). Margin slipping below 22% on slowing growth would require a larger acquisition to substantiate scale and would re-open downside toward the IPO band of $0.32. Everything else on this page is secondary.

---

Web Research

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Bottom Line from the Web

The web's load-bearing fact — under-emphasized in filings — is the EQT promoter sell-down: since IPO (Nov 2024) the sponsor has stepped from 100% to 50.95% across two Offer-for-Sale events at progressively higher prices, while the stock is down ~21% YTD with 100% of remaining promoter shares pledged. Layered on top: FY26 reported revenue growth of 29% is ~10pp overstated by FX and BroadPath (organic constant-currency was 15.0% FY, 19.4% Q4), and Capgemini–WNS (16.3x EV/EBITDA) sets a strategic ceiling that Sagility (10.8x) is already approaching. The forensic file is clean — no short-seller, no SEBI/SEC probe, no auditor qualifications — but the Q3 FY26 transcript shows BroadPath cross-sell stalled and the CFO seat has changed twice in six months without explanation.

What Matters Most

1. EQT promoter sell-down has been the dominant capital-markets event — and 100% of remaining promoter shares are pledged

The first OFS (May 27–28, 2025) disposed 70.3 crore shares (15.02% of equity) at a $0.44 floor, raising ~$311M. The second (Nov 14, 2025) was a block deal of 76.9 crore shares (16.4%) at $0.53, raising $407M — five global/domestic institutions (including Unifi Capital and ICICI Prudential) absorbed 8.6%. Promoter stake now sits exactly at the SEBI minimum public float comfort buffer; further reduction is discretionary, not mandated. (Sources: angelone.in 17 Nov 2025; moneycontrol.com block-deal coverage; trendlyne.com SAST filings; smartkarma.com lockup analysis 6 May 2025; marketsmojo.com — pledge disclosure)

2. FY26 headline growth is materially flattered by FX and BroadPath

CNBC TV18 (12 May 2026) and the Q3 FY26 transcript both flag the organic CC vs reported gap. Quartr's FY26 summary credits "declining finance costs and higher forex gains" for the 39.5% adj. PAT growth. Top-5 client growth was 11.7% YoY in FY26 — consistent with the diversification narrative but confirming the headline is doing heavy lifting. (Sources: cnbctv18.com 12 May 2026; quartr.com FY26 summary; tradealone.com FY26 review.)

3. Capgemini–WNS sets a hard valuation ceiling — Sagility is already three-quarters of the way there

Everest Group's Nov 2025 note framed the deal as creating "a global leader in Agentic AI-powered Intelligent Operations" — supporting the AI-led-services thesis Sagility is selling, while bounding the strategic premium. Among listed Indian peers, Inventurus Knowledge Solutions trades at ~39x trailing P/E and >18x EV/EBITDA; Sagility's ~20x P/E reflects a discount for promoter overhang and concentration. (Sources: everestgrp.com blog 16 Nov 2025; multiples.vc 29 May 2026; groww.in peer comparison; capgemini.com press release.)

4. CFO seat has turned over twice in six months — neither transition was explained on calls

(Sources: ETCFO 4 Nov 2025; bwcfoworld.com; Yahoo Finance executive list; sagility.com IR.)

5. Q4 FY26: in-line print, but stock fell 4.2% on margin and US-payer commentary

Q4 FY26: Revenue $216M (+29% YoY in INR, +19.4% CC); Adj EBITDA $53.7M (24.9% margin); Adj PAT $32.7M (+28%); reported net profit $27.5M (+41.2%). $30.7M new ACV across 18 clients. Despite the beat, the stock fell 4.2% to $0.45 on 12 May 2026 with 26.9M shares traded, after CEO commentary cited a "challenging US healthcare payer/provider environment." FY27 guidance: low double-digit constant-currency revenue growth; 24–25% adj EBITDA margin; complete debt repayment by end FY27. (Sources: whalesbook.com 12 May 2026; tradealone.com; in.investing.com.)

6. Analyst consensus: Buy, $0.58–$0.66 target — but MarketsMojo just downgraded to Hold

(Sources: marketscreener.com; trendlyne.com; tradebrains.in 27 Mar 2026; moneycontrol.com SIL27; marketsmojo.com 29 May 2026.)

7. Industry positioning solid — Everest Group Leader and NelsonHall Leader in 2026

Everest Group Healthcare Payer Intelligent Operations PEAK Matrix 2026 named Sagility a Leader (one of 33 evaluated providers), citing investments in Sagility Synchrony, SmarTec, and Sagi360 platforms. NelsonHall NEAT 2026 (Quality, Risk & Performance Management) likewise named Sagility a Leader, citing "AI-enabled pattern detection to support real-time audit." Both rankings position Sagility favorably vs diversified competitors (TCS, Infosys, Cognizant, Accenture, Genpact, EXL, WNS, Firstsource). (Sources: prweb.com 4 Mar 2026; sagility.com press release 19 Mar 2026.)

8. BroadPath cross-sell narrative is faltering

BroadPath was acquired 30 Jan 2025 for $58M (0.83x revenue), adding 1,600 employees and 30+ clients with a $70M revenue footprint in 2024. (Sources: alphastreet.com Q3 transcript; vccircle.com 30 Jan 2025.)

9. Customer concentration: ICRA confirms top-3 ≈ 65%, top-5 ≈ 78% of revenue

ICRA's October 2024 rating rationale and the September 2025 update consistently document that the top 3 customers = ~65% of revenue and top 5 = 78% in FY25, with 100% of revenue from US healthcare. Clients are not publicly identified — though Sagility states it serves "six of the top ten U.S. payers" and Optum is listed as a Capability Partner in its partner ecosystem, suggesting UnitedHealth Group adjacency. (Sources: icra.in rating rationale 9 Oct 2024 and 2025 update; sagility.com partner ecosystem.)

10. The forensic file is clean — but the SAR overhang and tax notice deserve attention

What did surface: (i) Jefferies Dec 2024 note flagged Share Appreciation Rights (SAR) compressing reported EBITDA margin ~230 bps in FY25; SAR is treated as "non-cash" in adjusted EBITDA but parent-level settlement and listed-entity dilution are not disclosed. (ii) Income tax demand was revised on 19 May 2026 from $10.5M to $6.0M — a 43% reduction following a rectification order. (iii) Auditors disclosed 13 sexual-harassment complaints in FY26 (11 disposed, 5 pending >90 days) — non-trivial for a 46,000-employee BPM. (Sources: BusinessToday Jefferies note 20 Dec 2024; marketscreener.com 18 May 2026; IIFL Directors' Report.)

Recent News Timeline

What the Specialists Asked

Governance and People Signals

Promoter holding has been absorbed primarily by domestic mutual funds (8.3% → 14.5%) and FIIs (6.0% → 10.0%), with the FII investor count expanding from 199 to 223. This is constructive sponsorship quality, not passive disinterest. (Sources: trendlyne.com Mar 2026 snapshot; upstox.com SAGILITY shareholding 5 Jun 2026.)

Management profile

CEO Ramesh Gopalan (b. 1968, IIT Dhanbad / IIM Ahmedabad) — directly carried over from HGS where he ran the global healthcare business; Glassdoor CEO approval 89%. CFO turnover: Sarvabhouman Srinivasan (in since Jan 2022) resigned Nov 2025; Abhishek Kayan appointed Deputy CFO; Srinivas Rathnam Mattapalli now seated as EVP & Group CFO by Q4 FY26. Independent director William Winkenwerder Jr (former US Asst Secretary of Defense for Health Affairs) is the standout healthcare credential. EQT representative Jimmy Mahtani sits on the board.

CEO compensation FY ending Dec 2025: $0.76M (Yahoo Finance). US-side leadership comp benchmarks (Salary.com): Chief Growth Officer ~$432K, EVP & General Counsel ~$337K. Glassdoor: 4.1/5 overall (1,220 reviews), 82% recommend, 82% positive business outlook; common cons are "low pay vs workload" and "metrics-focused TLs." Headcount 48,522 (Q4 FY26); attrition 26.6% (Q1 FY26) with a spike in Q4 voluntary attrition flagged on the call.

Industry Context

The healthcare BPM landscape has been reshaped by the Capgemini–WNS deal (16.3x EV/EBITDA strategic premium for an Agentic-AI-enabled BPS pure-play) — establishing Sagility as one of the few remaining listed vertical pure-plays. Listed Indian healthcare-services peers IKS (Inventurus Knowledge Solutions, $2.9B mkt cap, ~39x P/E) and Indegene ($1.3B, ~28x) are the cleanest direct comps; all three have underperformed since CY25 listing (IKS -13% YTD, Sagility -21%, Indegene -22% per Mint). Larger diversified competitors (TCS, Infosys, Cognizant, Accenture, Genpact, EXL, Firstsource) are present but not pure-plays.

Regulatory tailwinds: US healthcare ops spend reached ~$101.1B in 2023 (per Sagility RHP); Sagility's ~1.23% share leaves long runway. CMS rules increasingly require human-in-loop clinical decisions — a structural moat for Sagility's high-value member engagement revenue.

Regulatory headwinds: The HIRE Act (Sen. Moreno, 5 Sep 2025) — a 25% offshoring excise tax — remains alive but unscheduled for vote; tax press (MGO CPA Dec 2025, Cullen & Dykman Oct 2025) describes prospects as "unclear." Quantified margin impact would be material; carries it as a binary watch-item into FY27.

AI dynamic: Both threat (per-transaction rate deflation cited by JM Financial 20 May 2026; Nifty IT -13% YTD) and offense (18 AI use cases live across 8 clients; ~40% manual-effort reduction). Sagility appears better-positioned than diversified peers to navigate this — but the deflation overhang is real and likely to compress headline growth over the next ~12 months.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Web Watch in One Page

Five live monitors translate the report into a working watchlist, each tracking a load-bearing variable in the 5-to-10-year case rather than a generic news category. Watch #1 — outcome-based / Synchrony revenue disclosure — is the single most consequential signal in the thesis; the others anchor the structural floor under the stock (EQT pledge / next OFS), test the largest concentration tail (top-3 payer captive build-out à la Optum), track the named #1 competitive threat (Capgemini-WNS bundle), and price the regulatory tail on the INR cost-base advantage (HIRE Act and CMS offshore-PHI rules). Routine earnings, sell-side rating changes, and AI-deflation chatter are deliberately excluded — texture, not signal, already priced in the report.

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	Synchrony / outcome-based revenue moves from narrative to disclosure	Daily	Single biggest 5-10 year variable: turns a 21% structural-margin business into a 25%+ one and re-rates the multiple toward the Capgemini-WNS strategic ceiling.	First quantified Synchrony share of new ACV, first Synchrony P&L line, or a named Synchrony deal beyond the Convey Health / Simplify Healthcare alliance.
2	EQT promoter sell-down, pledge status, next OFS / block deal	Daily	100% of EQT's residual 50.95% is pledged. The next block-deal price (clean above $0.53 vs forced below $0.42) sets the structural floor and resolves the strategic-exit-vs-fire-sale debate binary on a single event.	New OFS, block deal, SAST filing, change in promoter pledge ratio, pledge-invocation news, or a SEBI Reg 30 strategic-bid disclosure.
3	Top-3 payer concentration — captive insourcing or renegotiation	Daily	Largest single tail risk; a 5% top-3 price-down is ~$23M / 250-400 bps of group margin. ICRA puts top-3 at 65% vs management's 59.9% — the Optum precedent is the named template.	Captive-GCC announcements at UnitedHealth / Optum, Elevance, Centene, CVS/Aetna, Cigna, Humana, HCSC, or BCBS plans; ICRA / CRISIL rating-rationale updates on top-3/top-5 concentration; named wallet-reduction disclosures.
4	Capgemini-WNS healthcare execution — strategic ceiling and bundle threat	Weekly	Sets the only observable strategic ceiling (16.3x EV/EBITDA) for Sagility's segment and is the named #1 24-month competitive threat.	Capgemini Healthcare / Intelligent Operations segment growth, named U.S. payer wins on a bundled IT + BPM proposal, analyst-grid re-rankings, or a further healthcare-BPM strategic deal that resets the take-out multiple.
5	U.S. offshoring excise (HIRE Act) and CMS / state DOI offshore PHI rules	Weekly	Low-probability, high-materiality tail: ~65-72% of Sagility's cost stack is INR/PHP labour; either change converts a structural margin advantage into a variable cost.	HIRE Act committee mark-up or Senate floor scheduling, CMS OCR enforcement on offshore PHI, state DOI rules on offshore TPA delivery, or IRS / Treasury implementation guidance.

Why These Five

These five map directly onto the report's open questions. The Verdict frames the next two FY27 prints as the bilateral test of margin durability and concentration disclosure; the Long-Term Thesis singles out outcome-based / Synchrony as the disclosure that changes the shape of the compounding curve rather than its slope; the Catalysts impact matrix ranks the next EQT block deal, the first quantified Synchrony number, and the ESOS structure as the three events that update the durable thesis rather than the next quarter. Watch #1 owns Synchrony; #2 owns the EQT exit / pledge tape; #3 owns the Optum-precedent failure mode at the named top-3 payers; #4 owns the Capgemini-WNS strategic-ceiling read across competitive performance and analyst grids; #5 owns the regulatory tail underneath the margin floor. Earnings prints, sell-side rating moves, and AI-deflation narrative-only flow are intentionally absent — the report has already metabolised them.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Where We Disagree With the Market

The market is pricing Sagility against the Nifty IT / Indian-BPM tape — a stock that has round-tripped from $0.61 to $0.42, de-rated from 38x to 20x P/E, treated as another casualty of GenAI per-transaction deflation — when the actual transaction comp set is Capgemini–WNS at 16.3x EV/EBITDA and Sagility is the only listed 100% U.S. healthcare BPM left on a global exchange. That framing interacts with three sharper disagreements: market debates top-3 concentration as a 59.9% vs 65% disclosure dispute when the underlying trend (72.4% → 59.9% with the same incumbents still growing 9.1% CC) is the rare moat signal worth pricing; market treats the 24.5% operating margin as cyclically FX-juiced when ~75% of the book is regulated-clinical work requiring licensed humans under CMS rules; and market reads the EQT promoter pledge plus OFS supply as headwind only, when the same structure — PE carve-out, pledge against external financing, BPEA IX already raised — historically resolves through a strategic exit, not a fire-sale. Each disagreement has a quarterly observable that closes the debate.

Variant Perception Scorecard

A 64 on variant strength reflects that the disagreement is real and quantifiable but not yet asymmetric to the upside — three of the four resolving signals (margin durability through FY27, top-3 trend, next OFS clearing price) are bilateral, not just confirmation paths. Consensus clarity is high (72) because we can point to specific signals — sell-side average TP $0.63, the 38x → 20x de-rating, the 29 May 2026 MarketsMojo downgrade, the death-cross technical setup, and the documented gap between ICRA's 65% and management's 59.9% top-3 numbers. Evidence strength is anchored on three independent reads: the Capgemini–WNS transaction multiple as a hard valuation reference, the four-year compounding record through three macro shocks, and the third-party analyst-grid Leader status across NelsonHall NEAT 2026, Everest PEAK 2026 and HFS Horizon 2026.

Consensus Map

The Disagreement Ledger

Disagreement #1 — wrong comp set. Consensus anchors on Firstsource (~22x P/E, 16% op margin, India-listed) and the broader Indian-BPM/IT-services cohort that has de-rated through CY26 on AI-deflation fear, treating Capgemini–WNS as a one-off. The report's evidence: Sagility is the only listed asset matching WNS's structural profile — 100% U.S. healthcare payer focus, three Leader designations, sub-1x net leverage — and the WNS take-out is the only observable strategic price for the segment. If the variant is right, the multiple should sit between Firstsource's ~22x and a strategic ceiling around 25-30x rather than today's 20x. The cleanest refutation: next two FY27 prints land with margin and growth no better than the diversified Indian BPM cohort — at which point the trading multiple is the right anchor.

Disagreement #2 — wrong concentration variable. Consensus treats ICRA top-3 at 65% (vs management's 59.9%) as the credibility-test version and applies a concentration discount on the higher number. The report's evidence: the direction — top-3 down 1,250 bps in three years while the same top-3 grew 9.1% CC and the count of >$20mn clients more than doubled — is the rarest moat signal observable, unambiguous on both ICRA's and management's series. If right, a 5-pp disclosure gap is methodology not thesis, and the trend should be priced as moat-widening. The cleanest refutation: Q1 FY27 KPI table shows top-3 reversing above 62%, or top-3 share holding flat while same-client growth slows below 7% CC.

Disagreement #3 — wrong margin denominator. Consensus reads the 24.5% margin as one rupee rally away from reverting to the 16-18% peer-average band, with the FY27 24-25% guide conceding the FX tailwind is unwinding. The report's evidence: ~75% of revenue is regulated-clinical work requiring licensed humans under CMS rules, the FX-neutralized structural floor is ~21% (still 500-700 bps above the diversified peer band), and outcome-based Synchrony contracting is a margin expander, not a defensive lever. If right, "FX unwind = margin reversion" is the wrong equation. The cleanest refutation: two consecutive quarters of margin below 22.5% with stable INR.

Disagreement #4 — wrong sign on EQT. Consensus reads a PE sponsor with 100% of its residual stake pledged as a forced seller of last resort with the next OFS clearing at a discount. The report's evidence: the setup — fresh fund (BPEA IX $15.6bn, Apr-26), stepping-up OFS clearing prices ($0.44 → $0.53), broadening institutional sponsorship (MF 8.3% → 14.5%, FII count 199 → 223), only listed pure-play in U.S. healthcare BPM — fits sponsors negotiating strategic exits, not dumping into the float. If right, the next OFS is a call option on a strategic premium, not a tape headwind. The cleanest refutation: a third OFS clearing below $0.42 with concentrated absorption (one or two large blocks at a discount).

Evidence That Changes the Odds

How This Gets Resolved

What Would Make Us Wrong

The cleanest way the variant view breaks is a Q1 FY27 print where adjusted EBITDA margin slips below 22.5% with INR roughly flat, organic constant-currency growth lands below 12%, and management concedes that the FY26 FX tailwind did more of the work than the regulated-clinical mix story implies. That combination refutes disagreement #3 and corrodes #1 — the transaction comp only works if the underlying margin profile is genuinely differentiated. The bear trigger configuration (sub-22% margin + sub-12% organic CC + 2%+ AI cannibalisation in the same print) is the single most efficient path to invalidation, and it sits at a hard date inside eight weeks. The asymmetry is not wider than that.

A second route to being wrong is on the concentration question. If the next two quarterly KPI tables show top-3 holding at 59-60% instead of continuing to fall, and same-client growth slows below 7% CC, then the "concentration falling while incumbents still grow" signal — the load-bearing argument in disagreement #2 — becomes a frozen line rather than a sequence. At that point ICRA's 65% disclosure is closer to the right risk pricing than management's 59.9%, and the focus-and-margin premium narrows toward the diversified-peer band. The forensic file is fair to flag that BroadPath's mechanical contribution to the FY26 diversification print is real — strip it and the organic concentration trend is shallower than the headline suggests.

The third asymmetric risk is on the EQT exit narrative. If the next OFS clears below $0.42 with concentrated absorption (one or two large blocks at a deep discount), or — worse — if a pledge-related news event surfaces, then disagreement #4 is broken not gradually but discontinuously. The variant view treats the pledge as a structure pointing toward a strategic exit; the bear treats it as a forced-seller signal pointing the other way. There is no middle ground between those two reads, and the resolution is binary on a single block-deal print. We have no visibility into the timing.

The honest fourth risk is regulatory and slower: if the HIRE Act (25% offshoring excise tax, Sen. Moreno, 5-Sep-25) advances to a Senate floor vote, or if CMS or state DOIs tighten offshore PHI handling rules, the cost-side of the variant view (INR/PHP wage arbitrage as a structural margin support) becomes a variable cost rather than a fixed advantage. The probability is low — tax press through Dec-25 called HIRE Act near-term prospects "unclear" — but the materiality is high. This is a tail we cannot price, and we should be honest that the variant view assumes the regulatory status quo on offshore delivery costs.

The first thing to watch is the Q1 FY27 adjusted EBITDA margin print in the last week of July 2026 — specifically whether it lands at or above 24% with INR flat and organic constant-currency growth at or above 14%. That configuration would resolve disagreements #2 and #3 and challenge the trading-cohort anchor.

---

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, multiples, percentages, share counts, and unitless technical indicators (RSI, volatility %) are unchanged.

Liquidity & Technical

A mid-cap-friendly tape with adequate institutional capacity but a bearish setup. Sagility trades roughly $7.6M per day, supports a five-day full position of approximately $7.25M at 20% participation, and sits in a confirmed post-IPO downtrend — price is 12.6% below the 200-day, the 50/200 death cross fired on 20 March 2026, and the stock has round-tripped from a $0.6518 all-time high last October back to $0.4214 with 30-day realized volatility unusually calm at 26.6% (below the 20th percentile). The grinding, low-volatility decline — not panic selling — is consistent with distribution rather than a flush, a pattern that historically resolves lower before it resolves higher.

1. Portfolio implementation verdict

Sagility offers institutionally implementable liquidity at mid-cap scale — about $7.6M traded per day, enough to build a five-day position of around $7.25M at 20% ADV — but the tape is in a confirmed downtrend with price below all four major moving averages and a recent death cross, so the technical stance is bearish on a 3-to-6 month horizon. The tape feature that matters most: the decline from $0.65 to $0.42 has happened on shrinking realized volatility (now in the calmest 20% of the post-IPO distribution), a profile more consistent with orderly distribution than capitulation — and one that typically lacks the wash-out signature buyers look for at a low.

A note on data: market-cap and share-count fields in the staged liquidity file are missing for Sagility, so position-percent-of-market-cap and supported-AUM figures are derived from raw ADV value and a $2.0B implied capitalization (≈4.68B shares × current price). Treat the AUM-tier ladder as indicative rather than exact.

2. Price snapshot strip

Beta is unavailable for this name — sub-19 months of trading history is too short for a reliable post-IPO beta. The 30-day realized vol stands in as the cleanest single risk measure.

3. Critical chart — price + 50/200-day SMA, full IPO history

Confirmed downtrend regime. Every major moving average (20d $0.4391, 50d $0.4399, 100d $0.4596, 200d $0.4823) sits above the current price. The chart breaks into three phases: a parabolic IPO honeymoon Nov 2024 to Feb 2025 ($0.35 to $0.62), six months of sideways base-building $0.45 to $0.52 through summer 2025, then the leg up to the $0.6518 all-time high on 31 October 2025, followed by the slow grind back down — round-tripping the entire 2025 rally.

4. Relative strength

The relative-performance file ships only the company's rebased series; no benchmark or sector series was captured for this NSE listing. We therefore cannot plot Sagility versus Nifty 50 or a healthcare-services peer basket on this page — only the absolute return picture is reliable. For context: the 1-year return is positive at +2.8%, but the 6-month return is -18.8% and YTD -23.1%, so any "stock is up year-over-year" framing flatters a setup that has materially deteriorated since November.

The return profile — positive 1y, negative every shorter window — is consistent with a stock that has put in a top and is rolling over while the trailing comp window still benefits from the prior advance.

5. Momentum — RSI(14) and MACD histogram

RSI at 39.8 is mid-band — not yet oversold, with room to fall before a technically supported bounce becomes likely. The mid-March 2026 dip pushed RSI to 24, a one-time oversold print that produced the mean-reversion rally to $0.4734 in mid-May. That rally has now failed: RSI has rolled back to 40, MACD histogram has flipped negative again after a brief bullish month, and the MACD line sits at -$0.0050 below a -$0.0028 signal. The momentum setup is consistent with further downside unless RSI prints another sub-30 oversold reading paired with a credible reversal day.

6. Volume, volatility and sponsorship

The spike to 557M shares on 30 October 2025 is far off the right-axis scale and almost certainly a one-year post-IPO lockup release. Volume since the February-March 2026 break has been mid-30s on heavy days and high teens on quiet ones; the most recent leg from $0.4734 back to $0.4214 unfolded on the LIGHTER side of the 50-day band. Distribution on light volume looks calm but lacks the capitulation signature buyers typically wait for before stepping in.

The two extreme volume days — 14.7x on 28 May 2025 and 14.2x on 30 October 2025 — line up with the six-month and twelve-month post-IPO lockup release windows for an IPO that priced 12 November 2024. The May day went down on the spike; the October day went up — but the October close ($0.6146) marked the local top, and the ATH ($0.6518) printed the very next day before the decline began. The pattern is consistent with a large sponsor selling into the run-up, with the buyer providing the spike volume.

The 30-day realized vol at 26.6% is in the calm regime — below the post-IPO 20th-percentile floor of 30.3%. During the mid-March panic dip vol spiked to 51%; today's print is roughly half that, even with price back near the lows. A grinding, low-volatility decline is a classic distribution signature. When the tape rolls over while vol drops, sellers are typically working out of size patiently without buyer-side urgency — a slow leak that historically resolves in a fast move once a catalyst lands.

7. Institutional liquidity panel

This stock is not in the deep-pool tier (mega-cap ADV exceeding $30M); it sits in the mid-cap tradable tier. Funds can take a meaningful position, but execution should be size-aware.

The annual turnover ratio and ADV-as-percentage-of-market-cap fields are missing in the staged liquidity file because share-count and market-cap data did not flow through to the technical pipeline. The raw ADV value ($7.6M) and supported-AUM derivation below are unaffected by this gap.

Fund-capacity table — given the ADV, this shows the maximum fund AUM that can take a position at common weights without exceeding 20% or 10% of ADV over five trading days.

In plain English: at 20% ADV participation, a five-day full position is approximately $7.25M. That comfortably accommodates a $145M fund taking a 5% weight, or a $362M fund at 2%. At a more conservative 10% ADV participation, the supported AUM halves — and a 10% position would only be appropriate for funds up to about $36M, which is too small for most institutional mandates. For typical mid-cap-focused mutual funds and L/S funds in the $200M-$1B range, a 1-3% position is comfortable, a 5% position is achievable with 5-10 trading days of patient execution, and a 10% position is capacity-constrained.

Liquidation runway — the staged file ships these fields as null because issuer-level share counts and market cap did not flow through. The implied runway below uses a working estimate of approximately $2.0B market capitalization, derived from the current price and a disclosed share count of approximately 4.68B.

These row numbers are indicative — the assumed market cap is a working estimate, not the source-of-truth field. A 1% issuer-level position takes roughly 2-3 weeks to exit at 20% participation; a 2% issuer-level position becomes a multi-week execution challenge that pushes into capacity-constrained territory.

Daily-range proxy. The 60-day median intraday range is 3.31%, comfortably above the 2.0% threshold that flags elevated impact cost. Translated: the bid-ask spread plus intraday slippage is meaningful for any block trade. Algorithmic execution over multiple sessions — VWAP-style — will materially beat aggressive same-day fills.

Conclusion for institutional readers. At 20% ADV participation, the largest size that cleanly clears the five-day threshold is approximately $7.25M (around 0.4% of estimated market cap). At a more conservative 10% participation, that halves to about $3.6M. The execution playbook is clear: build over 5-10 days using a patient algo, accept the ~3.3% daily range, and avoid trying to take size in a single session.

8. Technical scorecard + stance

Stance: bearish on a 3-to-6 month horizon, net score -3. The setup resembles a textbook post-IPO distribution: parabolic honeymoon, sideways base, secondary breakout to a fresh high on a lockup-release volume spike, then a methodical decline that has now confirmed via the death cross and is unfolding without the vol expansion typically associated with a flush low. The two levels to watch:

• $0.4823 — a daily close above the 200-day SMA, ideally with the 50-day turning higher behind it, would flip the trend read and support a re-rating to neutral.
• $0.3819 — a daily close below the 52-week low opens the path to a re-test of the IPO area around $0.32, with no significant horizontal support in between.

Liquidity is not the constraint. Institutional participation up to a 5% position at a $145M fund AUM is implementable in five days at 20% ADV; the constraint is the chart, not the order book. For a fundamentally-driven add, the indicated action is watchlist, with a starter position considered only on either a clean reclaim of $0.4823 or a flush below $0.3819 that prints sub-25 RSI alongside a reversal day. Building into the current slow grind risks averaging into a tape where sellers still have the upper hand.

---

Short Interest & Thesis — Sagility Ltd (SAGILITY)

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bottom line

Short interest is not decision-useful for Sagility. India does not publish aggregate short-interest for listed equities, no deterministic source is staged for this name, and broad web/forensic search across credible financial media and short-thesis databases surfaced zero short-seller reports, activist campaigns, accounting allegations, regulator probes, or borrow-pressure flags. The real market-structure risk — 100% of EQT's residual 50.95% promoter stake pledged against external financing, plus a methodical post-IPO distribution tape — is supply-side overhang, not short positioning, and is owned by the People and Web Research tabs.

1. What the data pipeline actually staged

The deterministic short-interest fetcher returned zero rows across every short-interest table because no public/official source for aggregate reported short interest is configured for the Indian market in this pipeline version. The manifest is explicit:

2. Source-classification scoreboard

To be explicit about what each category would and would not tell us:

Three of eight rows are unavailable because India's disclosure regime does not produce them; two are none surfaced despite explicit search by the forensic and web-research agents; only the technical setup carries any positioning colour, and it is not a "short" signal in the institutional sense.

3. Why the standard short-thesis ledger is empty

The forensic agent's web crawl and the web-research agent's broader search both ran explicit short-seller queries (Hindenburg-style dossier sites, "Sagility fraud", "Sagility short report", SEBI enforcement search, US SEC enforcement search, Indian audit-resignation news). The findings:

4. The crowding-vs-liquidity check we can do — and what it tells us

Even without a reported short-interest number, we can size what a hypothetical short position would have to look like to be considered "crowded" against this name's liquidity. The point is to show how cheap a meaningful short would be to cover, not to claim one exists.

5. Borrow / SLB — what we can and cannot say

SLB activity may exist for SAGILITY, but no public symbol-level borrow tape is available to confirm it, and dependency research mentions no locate friction or borrow-cost pressure. Absence of evidence is not evidence of absence — but tightness should not be assumed without it.

6. The market-structure pressure that is real (and is not short interest)

What looks like "short pressure" on the tape is actually three distinct, well-documented supply-side phenomena owned by other tabs. Re-stating them here so the short-interest read is correctly anchored:

7. Catalyst-interaction read (positioning ≠ short positioning)

For a PM running this name, the catalysts that would interact with positioning are not "short squeeze" risks — they are long-side capitulation / supply-shock risks. Documenting them here so the page does not pretend short positioning is the variable:

None of these are "squeeze" risks. Sagility's positioning risks are long-side asymmetric — more negative catalysts (OFS, pledge, margin miss) than positive (BroadPath cross-sell, sector takeout) in the visible window.

8. Peer context — what we would compare if we could

The Indian-listed peers (IKS, Firstsource) share Sagility's exact disclosure gap; the US-listed comps (EXL, Genpact) have FINRA bi-monthly data but trade in a different liquidity/holder regime, so their SI numbers don't tell you anything actionable about Sagility's setup. There is no meaningful peer-relative crowding read to build here.

9. Evidence quality and limitations (read this)

10. What would change the read

• A credible short-seller dossier (Hindenburg / Viceroy / Bonitas / Spruce Point / new entrant) targeting SAGILITY, EQT, or the carve-out structure.
• A SEBI show-cause notice, SEC inquiry, or auditor qualification — any of which would flip the forensic file.
• A material change in the Indian disclosure regime making aggregate short interest public.
• A jump in NSE SLB activity for SAGILITY visible in exchange data, or sell-side commentary flagging hard-to-borrow status.
• A promoter pledge default event — this would not be "short pressure" but it would trigger a supply shock the size of an EQT block deal at a price the market did not set.

Until any of those land, this page documents the absence of decision-useful short data rather than manufacturing a signal.